





# Handbook of Pathology Services







Third Edition 2022

#### **Editors**

Mr. Alex C.P. Leung Ms. Christina S.M. Long Leung Mr.Thomas H.C. Wong

Copies of this handbook can be obtained from the secretary of the Department of Pathology.

A web version is also available at "Department of Pathology" on https://www.hksh-hospital.com.



#### Standing (left to right):


Christina Long, Thomas Wong, Kith Tsui, Esda Ng, Patrick Lam, Matthew Ho, Dr. Chris Chan PhD, Chen Miu Wah, Kristi Lai, Chan Tsz Ming, Ryon Heung, Dr. Raymond Chan DHSc, Twinky Chan and Jack Lam

#### Seated (left to right):

Dr. John Nicholls, Dr. Tony Ma, Dr. Robert Collins, Dr. May Chan, Dr. Chan Wai Kong, Dr. Laurence Hou (Director of Histopathology & Cytology Division), Dr. Tsao Yen Chow (Head (Administrative)), Dr. Edmond Ma (Director of Clinical Pathology & Molecular Pathology Division), Dr. Jonpaul Zee, Dr. Bone Tang, Dr. Melody Hui and Mr. Alex Leung (Senior Medical Technologist in-charge)

## TABLE OF CONTENTS

| Preface                              | 4  | Test Turnaround Time         | 15 | Flow Cytometry                       | 60 | Test Panels / Packages            | 83 |
|--------------------------------------|----|------------------------------|----|--------------------------------------|----|-----------------------------------|----|
| ntroduction                          | 6  | Unlisted Tests               | 15 | Sleep Test                           | 61 | <b>Guidelines / Patient Notes</b> | 86 |
| General Information                  |    | Point-of-Care Testing (POCT) | 15 | Histopathology and Cytology Division |    | for Special Tests                 |    |
| Hours of Operation                   | 8  | Test Disciplines             |    | Histopathology                       | 62 | Appendix                          | 89 |
| Useful Contact Numbers               | 9  | Clinical Pathology Division  |    | Cytology - Gynaecological            | 64 | Index                             | 99 |
| How to Order Lab Tests               | 11 | Blood Bank                   | 17 | Cytology - Non-gynaecological        | 65 |                                   |    |
| Patient Identification Policy        | 12 | General Laboratory and       |    | Frozen Section                       | 66 |                                   |    |
| Standard Precautions for             | 12 | Send-out Test Services       | 18 | Molecular Pathology Division         |    |                                   |    |
| Specimen Handling                    |    | Clinical Chemistry           | 19 | Infectious Disease                   | 67 |                                   |    |
| Rejection of Unacceptable Specimens  | 13 | Clinical Haematology         | 41 | Molecular Haematopathology           | 70 |                                   |    |
| Unsatisfactory Analytic Results      | 14 | Clinical Microbiology        | 46 | Molecular Oncology                   | 76 |                                   |    |
| Critical Value Reporting Policy      | 14 | Clinical Immunology          | 49 | Health Assessment Packages           | 81 |                                   |    |
| Policy for the Disclosure of Results | 14 | Core Laboratory Service      | 58 |                                      |    |                                   |    |
| Confidentiality of Data              | 14 | Stem Cell                    | 59 |                                      |    |                                   |    |



With the rapid expansion of clinical services and the ever increasing demand for pathology support from different sub-specialty groups, it has become imperative that we publish a new edition of the Handbook in order to accommodate all the new information that have accumulated. Nevertheless, the aim of our Department remains the same, i.e. to provide a service that is fast, reliable and comprehensive. The Handbook remains a tool for easy reference to the wide range of services in our Department.

Of late, our HKSH Medical Group has been popularizing the concept of 'partnership in care'. This applies not just to the cooperation between doctors and nurses but also between all members of the Group including para-medicals and laboratories. In order to provide a better and reliable service, good communication must be maintained between users and the laboratory. We welcome information and feed-backs from all clinical staff.

Already, we have 2 pathologists in haematology, 2 pathologists in microbiology and 7 histopathologists collaborating closely with the clinicians. Our molecular laboratory also works hand-in-hand with our clinicians. Other aspects of laboratory service, including the standard of service, turn-around time etc. have also to be looked into.

We hope this Handbook will continue to serve as a ready reference for you and will also publish it as a soft copy so that you can download into your computer.

#### Dr. Y. C. Tsao

Administrative Director Department of Pathology

#### INTRODUCTION

The Third Edition of this handbook comes at a time when great strides are made in laboratory medicine, in which laboratory testing is not only reserved for diagnostic purpose but also intended to support the clinician in disease prognostication, treatment guidance, monitoring of progress and disease prevention. The laboratory closely partners with the clinician in the advancement of patient care and management.

Like the previous edition, the Third Edition of the Handbook of Laboratory Services is prepared with the laboratory user in mind, aiming to assist them in making the best use of the Pathology Services offered by HKSH Medical Group. Through consulting this booklet, laboratory investigations relevant to various body systems or clinical specialties can be selected and ordered.

Proper adherence to sample collection and handling guidelines will ensure accurate results with minimal delay. General procedures of requesting laboratory tests are described in the initial sections. Special attention must be drawn to the fact that serious error can occur as a result of patient misidentification. Hence we urge the proper completion of sample requisition form with the appropriate patient identifiers and clinical information. Our pathologists, scientists and technologists are always ready to assist in laboratory test selection.

There has been an impressive expansion of Molecular Pathology service provision that covers the scope of oncology testing, rapid infectious disease diagnostics and genetic testing. The Division of Molecular Pathology is equipped with state-of-the-art genome sequencers, automated molecular systems and cytogenomic workstations that enable the application of precision medicine to serve patient needs.

Point-of-care testing devices are introduced in the hospital to guide patient management decisions at the bedside. The Clinical Laboratory is responsible for instrument evaluation and quality assurance of these devices.

The complete list of laboratory tests can be found in subsequent sections grouped in disciplines under the three divisions of the department. Test information includes test names, sample requirements, methodologies, test frequency, test turnaround time and special remarks. We are only providing brief information of each test for easy referencing. More detailed specifications and indications of special tests are available under the Pathology Services Update in the Doctors' Corner of the Hospital homepage.

Besides laboratory diagnostics, we are also involved in direct patient related services, namely phlebotomy, urea breath testing, sleep apnoea (polysomnography), and electrocardiography.

The Clinical Laboratory is a certified phlebotomy training centre recognised by

In order to achieve and maintain excellent standard of services, the Department of Pathology emphasizes in quality management, staff training, external accreditation and communication. By adhering strictly to official occupation safety and health guidelines, we strive to provide a safe environment for staff through the minimization and management of workplace hazards and anticipation of risks.

Medical and technical staff of the Department is prepared to provide help and advice on the available laboratory investigations. As always, we welcome any comments and suggestions, and are committed to providing pathology services of the highest standards, to the ultimate benefit of our patients.

#### Dr. Edmond S. K. Ma

Director of Clinical and Molecular Pathology

the American Society of Clinical Pathology.

### **Hours of Operation**

|   | Normal Service  | Outside Office Hours                       |  |  |  |  |  |
|---|---|--|--|--|--|--|--|
| Clinical Pathology Division             |   |  |  |  |  |  |  |
| Blood Bank                              |   |  |  |  |  |  |  |
| Clinical Chemistry                      | 24 hours a day  | , 7 days a week                            |  |  |  |  |  |
| Clinical Haematology                    |   |  |  |  |  |  |  |
| Clinical Microbiology                   |   |  |  |  |  |  |  |
| Clinical Immunology and Serology        | 8:00 am to 4:00 pm<br>Monday to Saturday                  | N/A  |  |  |  |  |  |
| Stem Cell                               | 9:00 am to 5:00 pm Weekday<br>9:00 am to 1:00pm Saturday  | N/A  |  |  |  |  |  |
| Send-out Tests                          | 9:00 am to 5:00 pm Weekday<br>9:00 am to 1:00pm Saturday  | N/A  |  |  |  |  |  |
| Histopathology and<br>Cytology Division | 8:00 am to 6:00 pm Weekday<br>8:00 am to 1:00 pm Saturday | Frozen section cases<br>at an extra charge |  |  |  |  |  |
| Molecular Pathology Division            | 8:00 am to 6:00 pm Weekday<br>8:00 am to 6:00 pm Saturday | On call for special cases                  |  |  |  |  |  |

#### **Useful Contact Numbers**

| Administrative Director  Dr. Tsao Yen Chow  | 2835-8800 |
|---|-----------|
| Director, Clinical and Molecular Path<br>Dr. Ma Shiu Kwan, Edmond                                       | 0.5       |
| <b>Director, Histopathology and Cytolog</b> Dr. Hou Lee Tsun, Laurence                                  |           |
| Clinical Microbiologist  Dr. Yung Wai Hung, Raymond  Dr. Tang Siu Fai, Bone  Dr. Zee Sze Tsing, JonPaul | 2835-8969 |
| Consultant Haematologist  Dr. Choi Wai Lap, William   | 2835-8499 |

## **Consultant Histopathologist** Dr. Chan Kwok Mei, May ...... 2835-8771 Dr. Chan Wai Kong ...... 2835-8772

| Dr. Ma Kwok Fai, Tony   | 2835-7692 |
|---|-----------|
| Senior Medical Technologist In-charge Mr. Leung Chin Pang, Alex |           |
| Blood Bank Ms. Ng Hon Yi, Esda                                  | 2835-8793 |
| Clinical Chemistry  Mr Ho Kam Shing, Matthew                    | 2835-7083 |

| Ms. Lau Yin See  |
|--|
| <b>Clinical Microbiology</b> Mr. Chan Tsz Ming                             |
| Clinical Immunology & Serology  Ms. Lai Tsz Wan, Kristi                    |
| <b>General Laboratory and Send-out Test Services</b> Ms. Chen Miu Wah      |
| <b>Stem Cell</b> Mr. Wong Hin Ching, Thomas                                |
| <b>Histopathology and Cytology Division</b> Mr. Lam Chi Wai, Patrick       |
| Molecular Pathology Division  Dr. Chan Tsun Leung, Chris (Ph.D.) 2835-8779 |

Clinical Hasmatology

## **General Enquiries** Histopathology and Cytology ......2835-8839 Molecular Pathology......2835-8779 **Phlebotomy Hotline Facsimile Number** Clinical Pathology .......2835-8799 Histopathology and Cytology ......2834-6392 Molecular Pathology......2892-7558 **Department Secretary** ..2835-7032 **Hospital Operator**

......2572-0211

#### **How to Order Lab Tests**

Under normal circumstances, our team of highly trained phlebotomists is responsible for blood collection of inpatients and outpatients of the Hospital. In case of blood collection being done externally by doctors or nurses, please ensure that the blood is placed in appropriate containers for the required tests, clearly labelled and delivered promptly to our Department for processing. Incorrectly labelled / unidentified samples and forms will be rejected (See Rejection Criteria for details).

Please use the correct request form(s) for test(s) required. Patient demographics must be given, together with the date and time of collection. The test(s) must be ordered and signed by the attending doctor or attending nurse on his/her behalf. For phlebotomy requests, please send us the form as soon as possible so as to minimise delays in processing. Due to limited manpower, we might be unable to answer your calls during night time. And for urgent cases, please call the Hospital Operator, and we shall get back to you as soon as possible.

Outside specimens must be placed in securely sealed triple packaging, to which the request forms are also securely attached. (Refer to Standard Precautions for Specimen Handling).

#### **Patient Identification Policy**

It is the Group's policy that services are only rendered to patients upon presentation of valid identification documentations. Those who do not hold a HKID must provide other forms of identification.

#### **Standard Precautions for Specimen Handling**

- All specimens should be treated as infectious and handled using standard precautions.
- Specimens must be delivered to the laboratory in "triple-layer packaging" in accordance with the Group's guidelines.
- A leak-proof container must be used as a primary holder of the specimen, packed in a single secondary container.
- All secondary containers should be placed into an outer container or packaging / box during delivery. The outer container should be made of strong material that can be cleansed and disinfected, and should be labelled with biohazard warning signs.
- Appropriate personal protective equipment (PPE) must be worn when handling specimens.

#### Rejection of Unacceptable Specimens

All efforts will be made in attempting to process specimens. Specimens may be deemed unsuitable or unsafe for processing and thus rejected under the following circumstances:

- · Request forms without a unique patient identifier
- · Request forms without indication of test required
- Request forms without the name of requesting doctor
- Request forms with illegible writing
- Request forms contaminated with blood or body fluids
- Specimens without labelling
- Specimens in wrong container type
- Haemolyzed or insufficient amount of sample
- Spilled specimens, leaking or cracked tubes and containers
- Mismatched information on the forms and specimens

#### **Unsatisfactory Analytic Results**

The duty technologist will repeat the test with justification if the result(s) is/are considered doubtful. Samples are retaken if the duty supervisor remains unsatisfied with the results.

#### **Critical Value Reporting Policy**

Critical values are defined as laboratory results, found in pathological states, that show significant variations from normal ranges and are potentially life-threatening. Laboratory staff will verbally report these results over the phone directly to the doctor-in-charge so that immediate action can be taken. Nurses at of ward/centre / outside clinics will be informed if the doctor cannot be reached.

#### **Policy for the Disclosure of Results**

The Group prohibits disclosure of confidential information to parties not directly concerned with the test-requesting patient. Only doctors, ward nurses and other authorised persons will receive the results, which are given at the total discretion of the Department of Pathology.

#### **Confidentiality of Data**

The Department would like to reassure its users that all laboratory test results and patient data remain fully confidential.

#### **Test Turnaround Time**

The turnaround time of laboratory tests varies according to the type of tests required. In general, it ranges from 30 minutes for an urgent CBP to a few weeks for tests sent to other countries. Frequency and turnaround time of each test are provided in this Handbook for reference. As a large number of tests are processed every day, please indicate clearly on the request form if urgent results are expected. We shall make our best effort to cater to your needs.

#### **Unlisted Tests**

Please contact the Department at 2835-8702 for tests not listed in this Handbook. We will try our best to search for testing laboratories that suit your needs.

#### Point-of-Care Testing (POCT)

Point-of-care testing provides rapid critical test results at the patient's bedside, enabling clinicians to make informed treatment decisions promptly. All POCT testing devices are managed by the Department of Pathology, and we strive to provide accurate test instruments through vigorous quality control, maintenance schedules and parallel testing with laboratory instruments. POCT devices are currently available for bedside testing of some vital analytes at the Operating Theatre, Intensive Care Unit, Department of Diagnostic & Interventional Radiology and Cardiac Catheterization & Intervention Centre. For further enquiry, please call 2835-8790.



TEST DISCIPLINES

## CLINICAL PATHOLOGY DIVISION

Blood Bank (ext. 8793)

| Test Name                      | Ref. Range                       | Specimen         | Method                      | Test Frequency | Panel                  | Pledge TAT   | Remarks |
|--------------------------------|----------------------------------|------------------|-----------------------------|----------------|------------------------|--|---------|
| "Blood Group<br>Rh (D) typing" | Not applicable                   | EDTA whole blood | Forward &<br>Reverse typing | On arrival     | Immuno-<br>haematology | "Routine:<br>within 2 hours"                                     |         |
| Direct Coombs                  | Negative                         | EDTA whole blood | Serology                    | On arrival     | Immuno-<br>haematology | "Routine:<br>within 4 hours<br>after receipt of<br>the specimen" |         |
| Indirect<br>Coombs             | Negative                         | EDTA whole blood | Serology                    | On arrival     | Immuno-<br>haematology | "Routine:<br>within 4 hours"                                     |         |
| Cold Agglutinin                | <32                              | Serum            | Serology at 4°C             | On arrival     | Immuno-<br>haematology | 1 working day  |         |
| Warm<br>Agglutinin             | Negative                         | Serum            | Serology at 37°C            | On arrival     | Immuno-<br>haematology | "Routine:<br>within 4 hours"                                     |         |
| Warm<br>Agglutinin             | Negative                         | Serum            | Serology at<br>37 °C        | On arrival     | Immuno-<br>haematology | Urgent: 1 to 1½ hours Routine: within 4 hours                    |         |
| Crossmatch                     | Compatible                       | EDTA whole blood | Serology                    | On arrival     | Immuno-<br>haematology | "Routine: within 4 hours"  |         |
| Type & Screen                  | No irregular antibodies detected | EDTA whole blood | Serology                    | On arrival     | Immuno-<br>haematology | "Routine:<br>within 4 hours"                                     |         |
| Private Donor                  | Suitable for donation            | EDTA whole blood | Serology                    | On request     | Blood<br>Transfusion   | At least 7<br>working days                                       |         |
| Autologous<br>Transfusion      | Suitable for donation            | EDTA whole blood | Serology                    | On request     | Blood<br>Transfusion   | At least 7<br>working days                                       |         |

#### General Laboratory and Send-out Test Services (ext. 8702)

| Test Name        | Ref. Range | Specimen              | Method                    | Test Frequency | Pledge TAT     | Remarks  |
|------------------|------------|-----------------------|---------------------------|----------------|----------------|--|
| Urea Breath Test | < 4 Delta  | Carbon<br>dioxide gas | Infra-red<br>spectrometry | On request     | 2 working days | Patients should fast for at<br>least 4 hours before testing.<br>Some drugs are restricted,<br>please enquire |

Clinical Chemistry sample type notation:

AF - Ascitic Fluid CP - Citrated Plasma

CSF - Cerebral Spinal Fluid DF - Drain Fluid

EP - EDTA Plasma EW - EDTA Whole Blood

F - Fluoride Plasma HP - Heparinized Plasma

HW - Heparinized Whole Blood PF - Pleural Fluid

S - Serum U - Urine

WB - Whole Blood 24-hr U - 24 hour Urine

| Test Name                          | Ref. Range                                    | Specimen | Method                            | Test<br>Frequency | Panel                     | Pledge<br>TAT | Remarks  |
|------------------------------------|---|----------|-----------------------------------|-------------------|---------------------------|---------------|--|
| Adrenocorticotropic hormone (ACTH) | 1.6 - 13.9 pmol/L                             | EP       | ECLIA                             | Every<br>2 days   | Hormone                   | 2 days        | Transport<br>on ice,<br>separate<br>from cells<br>asap |
| Alanine aminotransferrase (ALT)    | M: <41 U/L                                    | HP       | IFCC, without Pyridoxal phosphate | On arrival        | Liver                     | 4<br>hours    |  |
| ,                                  | F: <33 U/L                                    |          |                                   |                   |                           |               |  |
| Albumin                            | 40 - 49 g/L                                   | HP       | BCG                               | On arrival        | Liver                     | 4<br>hours    |  |
| Alkaline phosphatase (ALP)         | M: 40 - 129 U/L                               | HP       | IFCC, AMP buffer                  | On arrival        | Liver                     | 4<br>hours    |  |
| ()                                 | F: 35 - 104 U/L                               |          |                                   |                   |                           |               |  |
| Allergen component IgE             | <=0.34 KU/L                                   | S        | ImmunoCAP                         | Daily             | Allergy                   | 5 days        | Peanut,<br>Egg, Milk                                   |
| Alpha-fetoprotein (AFP)            | <7.0 μg/L                                     | HP       | ECLIA                             | On arrival        | Tumor Marker              | 24<br>hours   |  |
| Amikacin                           | Peak<br>(Therapeutic):<br>34.2 - 42.8 µmol/L  | HP       | KIMS                              | On arrival        | Therapeutic drug<br>level | 4<br>hours    |  |
|                                    | Peak (Toxic):<br>>59.9 µmol/L                 |          |                                   |                   |                           |               |  |
|                                    | Trough<br>(Therapeutic):<br>8.6 - 17.1 µmol/L |          |                                   |                   |                           |               |  |
|                                    | Trough (Toxic): >17.1 µmol/L                  | HP       | KIMS                              | On arrival        | Therapeutic drug<br>level | 4<br>hours    |  |
| Ammonia                            | M: 16 - 60 μmol/L<br>F: 11 - 51 μmol/L        | EP       | Enzymatic                         | On arrival        | Liver                     | 4<br>hours    | Transport<br>on ice,<br>separate<br>from cells<br>asap |
| Amylase                            | 28 - 100 U/L                                  | HP       | IFCC, Enzymatic colorimetric      | On arrival        | Pancreas                  | 4<br>hours    |  |

| Test Name               | Ref. Range                                   | Specimen | Method                       | Test            | Panel                        | Pledge      | Remarks |
|-------------------------|--|----------|------------------------------|-----------------|------------------------------|-------------|---------|
|                         |  |          |                              | Frequency       |                              | TAT         |         |
| Amylase (drain fluid)   | N/A  | DF       | IFCC, Enzymatic colorimetric | On arrival      | Body fluid                   | 24<br>hours |         |
| Amylase, pancreatic     | 13 - 53 U/L                                  | HP       | Salivary amylase inhibition  | On arrival      | Pancreas                     | 4<br>hours  |         |
| Anti-thyroglobulin      | <115 KIU/L                                   | S        | ECLIA                        | Every<br>2 days | Thyroid                      | 2 days      |         |
| Apolipoprotein A1       | M: 1.10 - 2.05 g/L<br>F: 1.25 - 2.15 g/L     | S        | Turbidimetry                 | Daily           | Atherosclerosis risk markers | 24<br>hours |         |
| Apolipoprotein B        | M: 0.55 - 1.40 g/L<br>F: 0.55 - 1.25 g/L     | S        | Turbidimetry                 | Daily           | Atherosclerosis risk markers | 24<br>hours |         |
| Ascitic fluid- LDH      | <60% of plasma<br>total LDH                  | AF       | IFCC, Lactate to pyruvate    | On arrival      | Body fluid                   | 24<br>hours |         |
| Ascitic fluid - Glucose | >60% of plamsa glucose                       | AF       | Hexokinase                   | On arrival      | Body fluid                   | 24<br>hours |         |
| Ascitic fluid - Protein | <50% of plasma protein                       | AF       | Biuret method                | On arrival      | Body fluid                   | 24<br>hours |         |
| Aspartate               | M: <40 U/L                                   | HP       | IFCC, without Pyridoxal      | On arrival      | Liver                        | 4           |         |
| aminotransferase (AST)  | F: <32 U/L                                   |          | phosphate                    |                 |                              | hours       |         |
| beta-CrossLaps (CTX)    | M(18-30yr):<br>0.155 - 0.873 μg/L            | EP       | ECLIA                        | Every 2<br>days | Bone marker                  | 2 days      |         |
|                         | M(31-50yr):<br>0.093 - 0.630 μg/L            |          |                              |                 |                              |             |         |
|                         | M(51-70yr):<br>0.035 - 0.836 μg/L            |          |                              |                 |                              |             |         |
|                         | M(>70yr):<br><=0.854 μg/L                    |          |                              |                 |                              |             |         |
|                         | F(pre-<br>menopause):<br>0.025 - 0.573 µg/L  |          |                              |                 |                              |             |         |
|                         | F(post-<br>menopause):<br>0.104 - 1.008 µg/L |          |                              |                 |                              |             |         |

| Test Name                       | Ref. Range   | Specimen                          | Method                        | Test<br>Frequency | Panel        | Pledge<br>TAT | Remarks                           |
|---------------------------------|--|-----------------------------------|-------------------------------|-------------------|--------------|---------------|-----------------------------------|
| b-human chorionic               | M: <2 IU/L   | S                                 | ECLIA                         | On arrival        | Pregnancy    | 4             |                                   |
| gonadotropin (hCG)              | F(Non-<br>pregnant<br>premenopausal:<br><=1 IU/L                                   |                                   |                               |                   |              | hours         |                                   |
|                                 | F(Post-<br>menopausal):<br><=7 IU/L  |                                   |                               |                   |              |               |                                   |
| Bicarbonate (HCO <sub>3</sub> ) | 24 - 31 mmol/L   | HP                                | Enzymatic,<br>PEP carboxylase | On arrival        | Renal        | 4<br>hours    | Collected in air-proof container  |
| Bilirubin, conjugated           | <=6.8 µmol/L   | HP                                | Colorimetric,<br>Diazo method | On arrival        | Liver        | 4<br>hours    | Protect<br>from light             |
| Bilirubin, total                | <=21 μmol/L  | HP                                | Colorimetric,<br>Diazo method | On arrival        | Liver        | 4<br>hours    | Protect<br>from light             |
| Blood Gas                       | pH(arterial):<br>7.35 - 7.45   | Arterial/ Venous/<br>Capillary WB | Potentiometry/<br>Amperometry | On arrival        | Blood gas    | or<br>(c      | Transport<br>on ice<br>(collected |
|                                 | pH(Venous):<br>7.32 - 7.43   |                                   |                               |                   |              |               | in air-proof<br>container)        |
|                                 | pCO2(Arterial):<br>32.0 - 48.0 mmHg  |                                   |                               |                   |              |               |                                   |
|                                 | PCO <sub>2</sub> (Venous):<br>6-7 mmHg higher<br>than arterial<br>pCO <sub>2</sub> |                                   |                               |                   |              |               |                                   |
|                                 | pO <sub>2</sub> (Arterial): 83.0<br>- 108.0 mmHg                                   |                                   |                               |                   |              |               |                                   |
| CA125                           | <35 KAU/L  | S                                 | CMIA                          | On arrival        | Tumor Marker | 24<br>hours   |                                   |
| CA15.3                          | <28 KAU/L  | S                                 | CMIA                          | On arrival        | Tumor Marker | 24<br>hours   |                                   |
| CA19.9                          | <37 KAU/L  | S                                 | CMIA                          | On arrival        | Tumor Marker | 24<br>hours   |                                   |

| Test Name                                      | Ref. Range                    | Specimen   | Method                              | Test            | Panel          | Pledge      | Remarks                                     |
|--|-------------------------------|--|-------------------------------------|-----------------|----------------|-------------|---|
|  |                               |  |                                     | Frequency       |                | TAT         |   |
| CA72.4   | <6.9 KU/L                     | HP   | ECLIA                               | Every 2<br>days | Tumor Marker   | 2 days      |   |
| Calcium  | 2.15 - 2.55<br>mmol/L         | HP   | NM-BAPTA                            | On arrival      | Metabolic/Bone | 4<br>hours  | Included<br>albumin-<br>adjusted<br>calcium |
| Calcium, ionized                               | 1.15 - 1.33<br>mmol/L         | Ca-balanced HepWB (collected in air-proof container) | Direct ISE                          | On arrival      | Metabolic/Bone | 4<br>hours  | Transport<br>on ice                         |
| Carboxyhaemoglobin                             | Non-smokers: <3%              | Arterial/ Venous/<br>Capillary WB (collected         | Co-oximetry                         | On arrival      | Co-oximetry    | 4<br>hours  |   |
|  | Smokers: <10%                 | in air-proof container)                              |                                     |                 |                |             |   |
| Carcinoembryonic antigen (CEA)                 | Non-smokers:<br><5 µg/L       | S  | CMIA                                | On arrival      | Tumor Marker   | 24<br>hours |   |
|  | Smokers:<br><10 µg/L          |  |                                     |                 |                |             |   |
| CSF- Glucose                                   | approx. 60% of plasma glucose | CSF  | Hexokinase                          | On arrival      | CSF            | 2<br>hours  |   |
| CSF- Protein                                   | 150 - 450 mg/L                |  | Turbidimetry                        | On arrival      | CSF            | 2<br>hours  |   |
| CSF- Albumin                                   | <0.35 g/L                     |  | Turbidimetry                        | On arrival      | CSF            | 24<br>hours |   |
| CSF- IgG                                       | <0.034 g/L                    |  | Turbidimetry                        | On arrival      | CSF            | 24<br>hours |   |
| CSF- IgG Index                                 | <0.8                          | CSF, S   | Turbidimetry                        | On arrival      | CSF            | 24<br>hours |   |
| Chloride                                       | 98 - 107 mmol/L               | HP   | Indirect ISE                        | On arrival      | Renal          | 4<br>hours  |   |
| Cholesterol, total                             | Desirable <5.18<br>mmol/L     | HP   | Cholesterol oxidase/<br>Peroxidase  | On arrival      | Lipids         | 4<br>hours  |   |
| Cholesterol, total to<br>HDL-Cholesterol Ratio | Desirable <5.0                | HP   | Calculated from total<br>Chol & HDL | On arrival      | Lipids         | 4<br>hours  |   |

| Test Name            | Ref. Range   | Specimen     | Method                 | Test<br>Frequency | Panel               | Pledge<br>TAT | Remarks |
|----------------------|--|--------------|------------------------|-------------------|---------------------|---------------|---------|
| CKMB                 | M: <6.2 μg/L<br>F: <4.9 μg/L                       | HP           | ECLIA                  | On arrival        | Cardiac             | 2<br>hours    |         |
| Complement C3        | 0.81 - 1.57 g/L                                    | S            | Turbidimetry           | Daily             | Immune              | 24<br>hours   |         |
| Complement C4        | 0.129 - 0.392 g/L                                  | S            | Turbidimetry           | Daily             | Immune              | 24<br>hours   |         |
| Cortisol             | 6-10am:<br>133 -537 nmol/L                         | HP           | ECLIA                  | Daily             | Hormone             | 24<br>hours   |         |
|                      | 4-8pm:<br>68.2 - 327 nmol/L                        |              |                        |                   |                     |               |         |
| C-Reactive protein   | <5 mg/L  | HP           | Immunoturbidimetric    | On arrival        | Inflammatory marker | 4<br>hours    |         |
| Creatine Kinase (CK) | M: 39 - 308 U/L                                    | HP           | IFCC, Imidazole buffer | On arrival        | Cardiac             | 4             |         |
|                      | F: 26 - 192 U/L                                    |              |                        |                   |                     | hours         |         |
| Creatinine           | M: 62 - 106<br>μmol/L                              | HP           | Jaffe, Alk. Picrate    | On arrival        | Renal               | 4<br>hours    |         |
|                      | F: 44 - 80 µmol/L                                  |              |                        |                   |                     |               |         |
| Creatinine Clearance | M: 0.82 - 1.20<br>ml/s/sq.m                        | HP & 24-hr U | Jaffe, Alk. Picrate    | Daily             | Renal               | 24<br>hours   |         |
|                      | F: 0.72 - 1.11<br>ml/s/sq.m                        |              |                        |                   |                     |               |         |
| Cyclosporin A        | Therapeutic<br>(12hr post dose):<br>100 - 400 µg/L | EW           | CMIA                   | Daily             | Immunosuppressants  | 24<br>hours   |         |
|                      | (24hr post dose):<br>100 - 200 µg/L                |              |                        |                   |                     |               |         |
|                      | Toxic: >400 µg/L                                   |              |                        |                   |                     |               |         |
| Cytomegalovirus IgG  | N/A  | S            | CMIA                   | Daily             | Serology            | 2 days        |         |
| Cytomegalovirus IgM  | N/A  | S            | CMIA                   | Daily             | Serology            | 2 days        |         |

| Test Name   | Ref. Range                       | Specimen | Method | Test<br>Frequency | Panel   | Pledge<br>TAT | Remarks |
|---|----------------------------------|----------|--------|-------------------|---------|---------------|---------|
| Dehydroepiandrosterone sulfate (DHEA-S)   | M(<11yr):<br><3.9 µmol/L         | S        | CMIA   | Daily             | Hormone | 24<br>hours   |         |
|   | M(11-14yr):<br>0.5 -6.6 µmol/L   |          |        |                   |         |               |         |
| M(20-24yr):<br>6.5 - 14.6 µmol/L<br>M(25-34yr):<br>4.6 - 16.1 µmol/L<br>M(35-44yr):<br>3.8 - 13.1 µmol/L<br>M(45-54yr): | M(15-19yr):<br>1.2 - 10.4 µmol/L |          |        |                   |         |               |         |
|   | M(20-24yr):<br>6.5 - 14.6 µmol/L |          |        |                   |         |               |         |
|   | M(25-34yr):<br>4.6 - 16.1 µmol/L |          |        |                   |         |               |         |
|   |                                  |          |        |                   |         |               |         |
|   | M(45-54yr):<br>3.7 - 12.1 µmol/L |          |        |                   |         |               |         |
|   | M(55-64yr):<br>1.3 - 9.8 μmol/L  |          |        |                   |         |               |         |
|   | M(65-70yr):<br>6.2 - 7.7 μmol/L  |          |        |                   |         |               |         |
|   | F(<11yr):<br><3.8 µmol/L         |          |        |                   |         |               |         |
|   | F(11-14yr):<br>0.2 - 4.6 µmol/L  |          |        |                   |         |               |         |
|   | F(15-19yr):<br>1.7 - 13.4 µmol/L |          |        |                   |         |               |         |
| 3<br>F  | F(20-24yr):<br>3.6 - 11.1 µmol/L |          |        |                   |         |               |         |
|   | F(25-34yr):<br>2.6 - 13.9 µmol/L |          |        |                   |         |               |         |
|   | F(35-44yr):<br>2.0 - 11.1 µmol/L |          |        |                   |         |               |         |

| Test Name                                   | Ref. Range  | Specimen | Method                          | Test<br>Frequency | Panel                  | Pledge I<br>TAT | Remark: |
|---|---|----------|---------------------------------|-------------------|------------------------|-----------------|---------|
| Dehydroepiandrosterone<br>sulfate (DHEA-S)  | F(45-54yr):<br>1.5 - 7.7 µmol/L                         |          | CMIA                            | Daily             | Hormone                | 24<br>hours     |         |
|   | F(55-64yr):<br>0.8 - 4.9 µmol/L                         |          |                                 |                   |                        |                 |         |
|   | F(65-70yr):<br>0.9 - 2.1 µmol/L                         |          |                                 |                   |                        |                 |         |
| Digoxin                                     | Therapeutic:<br>1.0 - 2.6 nmol/L                        | S        | KIMS                            | On arrival        | Therapeutic drug level | 4<br>hours      |         |
|   | Toxic: >2.6 nmol/L                                      |          |                                 |                   |                        |                 |         |
| Estimated glomerular filtration rate (eGFR) | >60 ml/<br>min/1.73sq.m                                 | HP       | Modified MDRD equation          | On arrival        | Renal                  | 4<br>hours      |         |
| Estradiol (E2)                              | Follicular:<br>46 - 607 pmol/L                          | HP       | ECLIA                           | On arrival        | Fertility Hormone      | 24<br>hours     |         |
|   | Ovulation:<br>315 - 1828 pmol/L                         |          |                                 |                   |                        |                 |         |
|   | Luteal:<br>161 - 774 pmol/L                             |          |                                 |                   |                        |                 |         |
|   | Menopause:<br><201 pmol/L                               | HP       | ECLIA                           | On arrival        | Fertility Hormone      | 24<br>hours     |         |
|   | Pregnancy<br>(1st trimester):<br>789 - >15781<br>pmol/L |          |                                 |                   |                        |                 |         |
|   | M: 28 - 156<br>pmol/L                                   |          |                                 |                   |                        |                 |         |
| Ferritin                                    | M: 30 - 400 µg/L  | HP       | ECLIA                           | On arrival        | Anaemic marker         | 24<br>hours     |         |
|   | F: 13 - 150 µg/L  |          |                                 |                   |                        |                 |         |
| Fibrinogen antigen                          | 1.8 - 3.5 g/L   | СР       | Nephelometry                    | On arrival        | Coagulation            | 24<br>hours     |         |
| Folate, RBC                                 | Deficient <340 nmol/L                                   | EW       | Competitive<br>Immunoassay, FBP | Every<br>2 days   | Anaemic marker         | 2 days          |         |

|                                    |                                   |          |                                 | '                 |                   | (exi. o       | 1792)   |
|------------------------------------|-----------------------------------|----------|---------------------------------|-------------------|-------------------|---------------|---------|
| Test Name                          | Ref. Range                        | Specimen | Method                          | Test<br>Frequency | Panel             | Pledge<br>TAT | Remarks |
| Folate, serum                      | Deficient <10.0 nmol/L            | HP       | Competitive<br>Immunoassay, FBP | Every 2<br>days   | Anaemic marker    | 2 days        |         |
| Follicle stimulating hormone (FSH) | Follicular:<br>3.5 - 12.5 IU/L    | HP       | ECLIA                           | On arrival        | Fertility Hormone | 24<br>hours   |         |
|                                    | Ovulation:<br>4.7 - 21.5 IU/L     |          |                                 |                   |                   |               |         |
| Post-me<br>25.8 - 13               | Luteal:<br>1.7 - 7.7 IU/L         |          |                                 |                   |                   |               |         |
|                                    | Post-menopause: 25.8 - 134.8 IU/L |          |                                 |                   |                   |               |         |
|                                    | M: 1.5 - 12.4 IU/L                |          |                                 |                   |                   |               |         |
| Free T3                            | 3.1 - 6.8 pmol/L                  | HP       | ECLIA                           | On arrival        | Thyroid Hormone   | 24<br>hours   |         |
| Free T4                            | 12.0 - 21.9 pmol/L                | HP       | ECLIA                           | On arrival        | Thyroid Hormone   | 24<br>hours   |         |
| G6PD Quantitative                  | Age >3 months                     | EW       | Enzymatic                       | Daily             | Anaemia           | 2 days        |         |
|                                    | Normal: >6.10 U/g Hb              |          |                                 |                   |                   |               |         |
|                                    | Borderline:<br>2.41 - 6.10 U/g Hb |          |                                 |                   |                   |               |         |
|                                    | Deficient:<br><2.41 U/g Hb        |          |                                 |                   |                   |               |         |
|                                    | Age <= 3 months                   |          |                                 |                   |                   |               |         |
|                                    | Normal:<br>>9.61 U/g Hb           |          |                                 |                   |                   |               |         |
| !<br>:                             | Borderline: 3.86 - 9.61 U/g Hb    |          |                                 |                   |                   |               |         |
|                                    | Deficient:<br><3.86 U/g Hb        |          |                                 |                   |                   |               |         |
| Gamma-                             | M: 10 - 71 U/L                    | HP       | IFCC, Enzymatic                 | On arrival        | Liver             | 4             |         |
| glutamyltransferase<br>(GGT)       | F: 6 - 42 U/L                     |          | colorimetric                    |                   |                   | hours         |         |

| Test Name   | Ref. Range                   | Specimen | Method                            | Test            | Panel              |             | Remarks   |
|---|------------------------------|----------|-----------------------------------|-----------------|--------------------|-------------|---|
|   |                              |          |                                   | Frequency       |                    | TAT         |   |
| Globulin  | 23 - 38 g/L                  | HP       | Calculated from protein & albumin | On arrival      | Liver              | 4<br>hours  |   |
| Glucose   | Fasting:<br>3.9 - 5.6 mmol/L | HP/F     | Hexokinase                        | On arrival      | Diabetes           | 4<br>hours  | 8 hours<br>fasting.<br>Fluoride   |
|   | Random:<br>3.9 - 7.8 mmol/L  |          |                                   |                 |                    |             | bottle<br>must be<br>used if<br>sample<br>deliver<br>from<br>outside<br>lab |
| Glycohaemoglobin<br>HBA1c                                   | <6.5%                        | EW       | HPLC                              | Daily           | Diabetes           | 2 days      |   |
| Haptoglobin   | 0.32 - 1.97 g/L              | S        | Turbidimetry                      | Daily           | Specific Protein   | 2 days      |   |
| Hepatitis A virus IgG                                       | N/A                          | S        | CMIA                              | Every<br>2 days | Hepatitis Serology | 2 days      |   |
| Hepatitis A virus IgM                                       | N/A                          | S        | CMIA                              | Every<br>2 days | Hepatitis Serology | 2 days      |   |
| Hepatitis B virus<br>core antibody IgM<br>(HBcoreIgM)       | N/A                          | S        | CMIA                              | Every<br>2 days | Hepatitis Serology | 2 days      |   |
| Hepatitis B virus core<br>total antibody<br>(HBcore Ab)     | N/A                          | S        | CMIA                              | Daily           | Hepatitis Serology | 2 days      |   |
| Hepatitis B virus envelop antibody (HBeAb)                  | N/A                          | S        | CMIA                              | Daily           | Hepatitis Serology | 24<br>hours |   |
| Hepatitis B virus envelop<br>antigen (HBeAg)                | N/A                          | S        | CMIA                              | Daily           | Hepatitis Serology | 24<br>hours |   |
| Hepatitis B virus surface antibody (HBsAb)                  | N/A                          | \$       | CMIA                              | Daily           | Hepatitis Serology | 24<br>hours |   |
| Hepatitis B virus surface<br>antigen (HBsAg)<br>qualitative | N/A                          | S        | CMIA                              | Daily           | Hepatitis Serology | 24<br>hours |   |

| Test Name  | Ref. Range  | Specimen | Method                                   | Test<br>Frequency | Panel                          | Pledge<br>TAT | Remarks          |
|--|---|----------|--|-------------------|--------------------------------|---------------|------------------|
| Hepatitis B virus surface<br>antigen (HBsAg)<br>quantitative | N/A   | S        | CMIA                                     | Daily             | Hepatitis Serology             | 24<br>hours   |                  |
| Hepatitis C virus antibody (HCV)                             | N/A   | S        | CMIA                                     | Daily             | Hepatitis Serology             | 24<br>hours   |                  |
| High density lipoprotein cholesterol (HDL-C)                 | M: Desirable<br>>=1.55 mmol/L;<br>At risk <1.04<br>mmol/L | HP       | Homogeneous<br>enzymatic<br>colorimetric | On arrival        | Lipids                         | 4<br>hours    |                  |
|  | F: Desirable<br>>=1.55 mmol/L;<br>At risk <1.30<br>mmol/L |          |  |                   |                                |               |                  |
| High sensitive<br>C-Reactive protein<br>(hs-CRP)             | <3.0 mg/L   | S        | Nephelometry                             | Daily             | Atherosclerosis risk<br>marker | 24<br>hours   |                  |
| Homocysteine   | <= 12.0 µmol/L  | EP       | Enzymatic                                | Weekly            | Cardiovascular risk            | 7 days        | Transport on ice |
| Human Epididymis<br>protein (HE4)                            | Pre-menopause:<br><=70 pmol/L                             | S        | CMIA                                     | Daily             | Tumor Marker                   | 24<br>hours   |                  |
|  | Post-menopause: <=140 pmol/L                              |          |  |                   |                                |               |                  |
| Human growth hormone   | M(<11yr):<br>0.28 - 18.90 mIU/L                           | S        | ECLIA                                    | Every<br>2 days   | Hormone                        | 2 days        |                  |
|  | M(11-17yr):<br>0.23 - 32.40 mIU/L                         |          |  |                   |                                |               |                  |
|  | M(>17yr):<br><7.41 mIU/L                                  |          |  |                   |                                |               |                  |
|  | F(<11yr):<br>0.36 - 23.40 mIU/L                           |          |  |                   |                                |               |                  |

|  |  |          |                             |                   | <u> </u>            | `             |   |
|--|--|----------|-----------------------------|-------------------|---------------------|---------------|---|
| Test Name  | Ref. Range   | Specimen | Method                      | Test<br>Frequency | Panel               | Pledge<br>TAT | Remarks                                     |
| Human growth hormone   | F(11-17yr):<br>0.37 - 24.15 mIU/L<br>F(>17yr):<br>0.38 - 29.64 mIU/L | S        | ECLIA                       | Every<br>2 days   | Hormone             | 2 days        |   |
| Human<br>immunodeficiency virus<br>antibody/p24 antigen<br>(HIV Ag/Ab) | N/A  | S        | CMIA                        | Daily             | Serology            | 24<br>hours   |   |
| Immunofixation   | N/A  | S        | Agarose gel electrophoresis | Daily             | Paraprotein         | 5 days        |   |
| Immunoglobulin IgA   | 0.85 - 4.99 g/L  | S        | Turbidimetry                | Daily             | Immunoglobulin      | 24<br>hours   |   |
| Immunoglobulin IgE, allergen specific                                  | <=0.34 KU/L  | S        | ImmunoCAP                   | Twice per<br>week | Allergy panel       | 5 days        |   |
| Immunoglobulin IgE,<br>total   | <100 KU/L  | S        | ImmunoCAP                   | Twice per<br>week | Allergy panel       | 5 days        |   |
| Immunoglobulin IgG   | 6.10 - 16.16 g/L   | S        | Turbidimetry                | Daily             | Immunoglobulin      | 24<br>hours   |   |
| Allergen speciic<br>Immunoglobulin IgG<br>and IgG4                     | N/A  | S        | ImmunoCAP                   | Weekly            | Allergen components | 5 days        | Egg white,<br>Egg yolk,<br>Peanut &<br>Milk |
| Immunoglobulin IgM   | 0.35 - 2.42 g/L  | S        | Turbidimetry                | Daily             | Immunoglobulin      | 24<br>hours   |   |
| Immunoglobulin<br>subtype G4 (IgG4)                                    | 0.04 - 0.86 g/L  | S        | Turbidimetry                | Daily             | Immunoglobulin      | 24<br>hours   |   |
| Inorganic phosphorus   | 0.81 - 1.45<br>mmol/L  | HP       | Phosphomolybdate formation  | On arrival        | Metabolic/Bone      | 4<br>hours    |   |
| Insulin  | 18 - 173 pmol/L  | HP       | ECLIA                       | On arrival        | Hormone             | 24<br>hours   |   |

| Test Name                                   | Ref. Range  | Specimen | Method  | Test            | Panel                       | Pledge      | Remarks   |
|---|---|----------|---|-----------------|-----------------------------|-------------|---|
|   |   |          |   | Frequency       |                             | TAT         |   |
| Iron  | M: 11.0 - 28.0<br>μmol/L<br>F: 6.6 - 26.0<br>μmol/L | HP       | FerroZine<br>method without<br>deproteinization | On arrival      | Anaemia                     | 4<br>hours  |   |
| Lactate                                     | 0.5 - 2.2 mmol/L                                    | F        | Enzymatic colorimetric                          | On arrival      | Metabolic                   | 4<br>hours  | Transport on ice. Serparate from blood cells ASAP |
| Lactate dehydrogenase                       | M: 135 - 225 U/L                                    | HP       | IFCC, Lactate to                                | On arrival      | Cardiac                     | 4           |   |
| (LDH)                                       | F: 135 - 214 U/L                                    |          | pyruvate  |                 |                             | hours       |   |
| Lipoprotein(a)                              | <75 nmol/L  | S        | Immunoturbidimetric                             | Every<br>2 days | Atherosclerosis risk marker | 2 days      |   |
| Low density lipoprotein cholesterol (LDL-C) | Optimal:<br><2.59 mmol/L                            | HP       | Homogeneous<br>enzymatic<br>colorimetric        | On arrival      | Lipids                      | 4<br>hours  | Direct<br>measurement                             |
|   | Near optimal:<br>2.59 - 3.34<br>mmol/L              |          |   |                 |                             |             |   |
|   | Borderline high:<br>3.35 - 4.12<br>mmol/L           |          |   |                 |                             |             |   |
|   | High:<br>4.13 - 4.90<br>mmol/L                      |          |   |                 |                             |             |   |
|   | Very high:<br>>=4.91 mmol/L                         |          |   |                 |                             |             |   |
| Lutinizing hormone (LH)                     | Follicular:<br>2.4 - 12.6 IU/L                      | HP       | ECLIA   | On arrival      | Fertility Hormone           | 24<br>hours |   |
|   | Ovulation:<br>14.0 - 95.6 IU/L                      |          |   |                 |                             |             |   |
|   | Luteal:<br>1.0 - 11.4 IU/L                          |          |   |                 |                             |             |   |

| Test Name  | Ref. Range                                 | Specimen   | Method                        | Test       | Panel                  | Pledae      | Remarks  |
|--|--|--|-------------------------------|------------|------------------------|-------------|--|
|  |  |  |                               | Frequency  |                        | TAT         |  |
| Lutinizing hormone (LH)  | Post-menopause:<br>7.7 -58.5 IU/L          | HP   | ECLIA                         | On arrival | Fertility Hormone      | 24<br>hours |  |
|  | M: 1.7 -8.6 IU/L                           |  |                               |            |                        |             |  |
| Magnesium  13-20yr: 0.70 - 0.91 mmol/L  21-60yr: 0.66 - 1.07 mmol/L  61-90yr: 0.66 - 0.99 mmol/L | 0.70 - 0.91                                | HP   | Colorimetric,<br>Xylidyl blue | On arrival | Metabolic              | 4<br>hours  |  |
|  | 0.66 - 1.07                                |  |                               |            |                        |             |  |
|  | 0.66 - 0.99                                |  |                               |            |                        |             |  |
|  | >90yr:<br>0.70 - 0.95<br>mmol/L            | НР   | Colorimetric,<br>Xylidyl blue | On arrival | Metabolic              | 4<br>hours  |  |
| Methaemoglobin   | <=1.5 %                                    | Arterial/Venous/<br>Capillary WB (collected<br>in air-proof container) | Co-oximetry                   | On arrival | Co-oximetry            | 4<br>hours  |  |
| Methotrexate   | 24hr post dose:<br>Toxic >10.0<br>umol/L   | HP<br>(Without gel, double-<br>spin)                                   | CMIA                          | Daily      | Therapeutic drug level | 24<br>hours | Wrap in<br>foil, Protect<br>from light,<br>double- |
|  | 48hr post dose:<br>Toxic >1.0 umol/L       |  |                               |            |                        |             | spin   |
|  | 72hr post dose:<br>Toxic >0.1 umol/L       |  |                               |            |                        |             |  |
| Microalbumin   | Random urine: <30 mg/L                     | U  | Immunoturbidimetric           | On arrival | Renal                  | 24<br>hours |  |
|  | 24 hour urine:                             |  |                               |            |                        |             |  |
|  | Normal:<br><=28.8 mg/day                   |  |                               |            |                        |             |  |
|  | Micro<br>albuminuria: 28.8<br>- 288 mg/day |  |                               |            |                        |             |  |

| Test Name  | Ref. Range                             | Specimen | Method   | Test<br>Frequency | Panel          | Pledge<br>TAT | Remarks |
|--|--|----------|--|-------------------|----------------|---------------|---------|
| Microalbumin   | Overt<br>albuminuria:<br>>288 mg/day   | U        | Immunoturbidimetric                                      | On arrival        | Renal          | 24<br>hours   |         |
| Microalbumin to creatinine ratio                                     | <1.92 mg/mmol                          | U        | Calculated from<br>Microalbumin &<br>Creatinine, urinary | On arrival        | Renal          | 24<br>hours   |         |
| Myoglobin  | M: 28 - 72 μg/L                        | S        | ECLIA  | Every             | Cardiac marker | 2 days        |         |
|  | F: 25 - 58 µg/L                        |          |  | 2 days            |                |               |         |
| Neonatal Bilirubin   | Full Term<br>Newborn                   | HW       | Optical  | On arrival        | Neonatal       | 1 hour        |         |
|  | up to 24 hours:<br>34 - 103 µmol/L     |          |  |                   |                |               |         |
|  | up to 48 hours:<br>103 - 171 µmol/L    |          |  |                   |                |               |         |
| 3 - 5 0  | 3 - 5 days:<br>68 - 137 µmol/L         |          |  |                   |                |               |         |
|  | Premature<br>Newborn                   |          |  |                   |                |               |         |
|  | up to 24 hours:<br>17 - 137 µmol/L     |          |  |                   |                |               |         |
|  | up to 48 hours:<br>103 - 205 µmol/L    |          |  |                   |                |               |         |
|  | 3 - 5 days:<br>171 - 239 µmol/L        |          |  |                   |                |               |         |
| Non-HDL-Cholesterol  | Desirable<br><4.20 mmol/L              | HP       | Calculated from total<br>Chol & HDL                      | On arrival        | Lipids         | 4<br>hours    |         |
| N-terminal prohormone<br>of brain natriuretic<br>peptide (NT-proBNP) | Rule out acute<br>CHF: <35.5<br>pmol/L | HP       | ECLIA  | On arrival        | Cardiac marker | 2<br>hours    |         |
|  | Age straified cutoff for acute CHF     |          |  |                   |                |               |         |

| Test Name                                    | Ref. Range                      | Specimen | Method                    | Test<br>Frequency | Panel                  | Pledge<br>TAT | Remarks  |
|--|---------------------------------|----------|---------------------------|-------------------|------------------------|---------------|--|
| N-terminal prohormone of brain natriuretic   | <50yr:<br>>53.3 pmol/L          | HP       | ECLIA                     | On arrival        | Cardiac marker         | 2<br>hours    |  |
| peptide (NT-proBNP)                          | 50-75yr:<br>>106.6 pmol/L       |          |                           |                   |                        |               |  |
|  | >75yr:<br>>213.1 pmol/L         |          |                           |                   |                        |               |  |
| Osmolality, plasma                           | 284 - 306<br>mOsm/kg            | HP       | Freezing point depression | On arrival        | Metabolic              | 24<br>hours   |  |
| Osmolality, urine                            | 50 - 1200<br>mOsm/kg            | U        | Freezing point depression | On arrival        | Metabolic              | 24<br>hours   |  |
| Osteocalcin                                  | 9 - 42 μg/L                     | EP       | ECLIA                     | Every<br>2 days   | Bone marker            | 2 days        |  |
| Parathyroid hormone (PTH)                    | 1.6 - 6.9 pmol/L                | EP       | ECLIA                     | Daily             | Parathyroid            | 24<br>hours   |  |
| Phenytoin                                    | Therapeutic: 39.6 - 79.2 µmol/L | S        | KIMS                      | On arrival        | Therapeutic drug level | 4<br>hours    |  |
| Pleural fluid-Adenosine deaminase            | <35 U/L                         | PF       | Enzymatic                 | On arrival        | Body fluid             | 24<br>hours   |  |
| Pleural fluid-Glucose                        | >50% of plasma<br>glucose       | PF       | Hexokinase                | On arrival        | Body fluid             | 24<br>hours   |  |
| Pleural fluid-Protein                        | <50% of plasma<br>protein       | PF       | Biuret method             | On arrival        | Body fluid             | 24<br>hours   |  |
| Pleural fluid-Lactate<br>dehydrogenase (LDH) | <60% of plasma<br>total LDH     | PF       | IFCC, Lactate to pyruvate | On arrival        | Body fluid             | 24<br>hours   |  |
| Potassium                                    | 3.2 - 4.8 mmol/L                | HP       | Indirect ISE              | On arrival        | Renal                  | 4<br>hours    | Separate<br>plasma<br>if sample<br>deliver<br>from<br>outside<br>lab |
| Prealbumin                                   | 0.20 - 0.40 g/L                 | S        | Turbidimetry              | Daily             | Nutritional assessment | 24<br>hours   |  |

| Test Name                               | Ref. Range  | Specimen | Method                      | Test<br>Frequency | Panel               | Pledge<br>TAT | Remarks |
|---|---|----------|-----------------------------|-------------------|---------------------|---------------|---------|
| Procalcitonin                           | Bacterial infection<br>unlikely<br><0.15 ng/ml                          | HP       | ECLIA                       | Daily             | Inflammatory marker | 24<br>hours   |         |
|   | Systemic or<br>severe localized<br>bacterial<br>infection<br>>2.0 ng/ml | HP       | ECLIA                       | Daily             | Inflammatory marker | 24<br>hours   |         |
| Progesterone                            | Follicular:<br><2.8 nmol/L  | HP       | ECLIA                       | Daily             | Fertility Hormone   | 24<br>hours   |         |
|   | Ovulation:<br><38.1 nmol/L  |          |                             |                   |                     |               |         |
|   | Luteal:<br>5.8 - 75.9 nmol/L  |          |                             |                   |                     |               |         |
|   | Post-menopause: <0.6 nmol/L   |          |                             |                   |                     |               |         |
|   | M: <0.6 nmol/L  |          |                             |                   |                     |               |         |
| Prolactin                               | Non-pregnant:<br>102 - 496 mlU/L  | HP       | ECLIA                       | Daily             | Fertility Hormone   | 24<br>hours   |         |
|   | M: 86 - 324 mIU/L   |          |                             |                   |                     |               |         |
| Prostate specific antigen, free (F-PSA) | <0.93 µg/L  | S        | CMIA                        | Daily             | Tumor Marker        | 24<br>hours   |         |
| Prostate specific antigen, total (PSA)  | M(<60yr):<br><4.0 μg/L  | S        | CMIA                        | Daily             | Tumor Marker        | 24<br>hours   |         |
|   | M(60-69yr):<br><5.0 μg/L  |          |                             |                   |                     |               |         |
|   | M(70-79yr):<br><7.1 μg/L  |          |                             |                   |                     |               |         |
|   | M(>79yr):<br><5.9 μg/L  |          |                             |                   |                     |               |         |
| Protein electrophoresis                 | N/A   | S        | Agarose gel electrophoresis | Daily             | Paraprotein         | 5 days        |         |

| Test Name                              | Ref. Range                                       | Specimen | Method        | Test            | Panel       | Pledge      | Remarks |
|--|--|----------|---------------|-----------------|-------------|-------------|---------|
|  |  |          |               | Frequency       |             | TAT         |         |
| Protein, total                         | 66 - 87 g/L                                      | HP       | Biuret method | On arrival      | Liver       | 4<br>hours  |         |
| Rheumatoid factor (RF)                 | <14 KU/L   | S        | Turbidimetry  | Every<br>2 days | Arthritis   | 2 days      |         |
| Rubella virus IgG                      | N/A  | S        | CMIA          | Daily           | Serology    | 24<br>hours |         |
| Rubella virus IgM                      | N/A  | S        | CMIA          | Every<br>2 days | Serology    | 2 days      |         |
| SARS-CoV-2 virus IgG                   | Negative<br><1.4 Index<br>Positive<br>≥1.4 Index | S        | CMIA          | Daily           | Serology    | 24<br>hours |         |
| SARS-CoV-2 virus IgG<br>quantitative   | Negative<br><50 AU/ml<br>Positive<br>≥50 AU/ml   | S        | CMIA          | Daily           | Serology    | 24<br>hours |         |
| SARS-CoV-2 virus IgM                   | Negative<br><1.0 Index<br>Positive<br>≥1.0 Index | S        | CMIA          | Daily           | Serology    | 24<br>hours |         |
| Serum free light chains                | Free kappa 3.30 - 19.40 mg/L                     | S        | Turbidimetry  | Daily           | Paraprotein | 24<br>hours |         |
|  | Free lambda 5.71 - 26.30 mg/L                    |          |               |                 |             |             |         |
|  | Kappa/Lambda<br>ratio: 0.26 - 1.65               |          |               |                 |             |             |         |
| Serum IgA heavy light chain pair assay | IgA kappa:<br>0.588 - 2.984 g/L                  | S        | Turbidimetry  | Daily           | Paraprotein | 24<br>hours |         |
|  | IgA lambda:<br>0.432 - 2.035 g/L                 |          |               |                 |             |             |         |
|  | IgA kappa/<br>lambda ratio:<br>0.91 - 2.42       |          |               |                 |             |             |         |

| Test Name   Ref. Range   Specimen   Method   Test   Panel   Pladge   Remarks   TAT   | Cili lical Chemistry (CXI. 6772) |                        |          |                     |            |             |        |         |
|--|----------------------------------|------------------------|----------|---------------------|------------|-------------|--------|---------|
| Serum IgG heavy light chain pair assay  Au3 = 9,78 g/L IgG kappa/  | Test Name                        | Ref. Range             | Specimen | Method              | Test       | Panel       | Pledge | Remarks |
| chain pair assay  A 0.3 - 9.78 g/L IgG lambdat: IgG lambdat: IgG kappa/ IgG kappa: O 19 - 1.63 / L IgM lambdat: O 12 - 1.01 g/L IgM kappa/ Igm  |                                  |                        |          |                     | Frequency  |             | TAT    |         |
| Serum IgM heavy light Chain pair assay   IgM kappa:   I   |                                  |                        | S        | Turbidimetry        | Daily      | Paraprotein |        |         |
| Serum IgM heavy light chain pair assay  Serum IgM kappa:  0.19 - 1.63 /L  IgM kappa: 0.12 - 1.01 g/L  IgM kappa/ Iambda ratio: 1.18 - 2.74  Serum immunofixation  N/A  Serum immunofixation  Daily  Serum immunofixation  Anaemia  2 days  Serum immunofixation  Anaemia  2 days  Serum immunofixation  Soluble Transferrin  Receptor (sTIR)  M: 1.80 - 4.70  mg/L  F: 1.78 - 4.59  mg/L  Syphilis Treponema pallicum total antibody (TPAb)  N/A  Serum immunofixation  Immunoturbidimetric  Serum immunofixation  Serum immunofixat |                                  |                        |          |                     |            |             |        |         |
| chain pair assay 0.19 - 1.63 /L IgM lambda: 0.12 - 1.01 g/L IgM kappa/ IgM bappa/ IgM ba |                                  | lambda ratio:          |          |                     |            |             |        |         |
| Serum immunofixation   N/A   S   Agarose gel electrophoresis   Daily   Paraprotein   5 days  |                                  |                        | S        | Turbidimetry        | Daily      | Paraprotein |        |         |
| Serum immunofixation 1.18 - 2.74  Serum immunofixation N/A  S  Agarose gel electrophoresis  CMIA  Daily Therapeutic drug level  Toxic: >20 µg/L Toxic: >20 µg/L  HP  Indirect ISE On arrival  Renal  Anaemia  Soluble Transferrin Receptor (sTfR)  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  Agarose gel electrophoresis  EW  CMIA  Daily Therapeutic drug level  Therapeutic drug level  Anaemia  2 days  CMIA  Daily Serology  Anaemia  2 days  CMIA  Daily Therapeutic drug level   |                                  | 0                      |          |                     |            |             |        |         |
| Sirolimus   Therapeutic: 3 - 20 µg/L   Toxic: >20 µg/L   HP   Indirect ISE   On arrival   Renal   4 hours  |                                  | lambda ratio:          |          |                     |            |             |        |         |
| 3 - 20 μg/L Toxic: >20 μg/L Sodium  134 - 148 mmol/L Receptor (sTfR)  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  3 - 20 μg/L Toxic: >20 μg/L HP Indirect ISE On arrival Renal 4 hours  Every 2 days  CMIA Daily Serology Therapeutic: 3 - 20 μg/L  EW CMIA Daily Therapeutic drug level hours  | Serum immunofixation             | N/A                    | S        |                     | Daily      | Paraprotein | 5 days |         |
| Sodium 134 - 148 mmol/L HP Indirect ISE On arrival Renal 4 hours  Soluble Transferrin Receptor (sTfR) M: 1.80 - 4.70 mg/L F: 1.78 - 4.59 mg/L  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus Therapeutic: 3 - 20 µg/L EW CMIA Daily Therapeutic drug level hours   | Sirolimus                        |                        | EW       | CMIA                | Daily      |             |        |         |
| Soluble Transferrin Receptor (sTfR)  M: 1.80 - 4.70 mg/L F: 1.78 - 4.59 mg/L  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  M: 1.80 - 4.70 mg/L F: 1.78 - 4.59 mg/L  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  M: 1.80 - 4.70 mg/L F: 1.78 - 4.59 mg/L  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  M: 1.80 - 4.70 mg/L Fevery 2 days  CMIA  Daily  Therapeutic drug level  Serology  Therapeutic drug level  Hours   |                                  | Toxic: >20 µg/L        |          |                     |            |             |        |         |
| Receptor (sTfR)  mg/L F: 1.78 - 4.59 mg/L  Syphilis Treponema pallidum total antibody (TPAb)  Tacrolimus  mg/L S CMIA  Daily  Serology  4 hours  CMIA  Daily  Therapeutic: 3 - 20 µg/L  EW  CMIA  Daily  Therapeutic drug level hours  | Sodium                           | 134 - 148 mmol/L       | HP       | Indirect ISE        | On arrival | Renal       | -      |         |
| pallidum total antibody (TPAb)  Tacrolimus  Therapeutic: 3 - 20 µg/L  Tacrolimus  Therapeutic: 24 hours  |                                  | mg/L<br>F: 1.78 - 4.59 | S        | Immunoturbidimetric |            | Anaemia     | 2 days |         |
| 3 - 20 µg/L level hours  | pallidum total antibody          | N/A                    | S        | CMIA                | Daily      | Serology    |        |         |
| Toxic: >25 µg/L  | Tacrolimus                       |                        | EW       | CMIA                | Daily      |             |        |         |
| 1 💸  |                                  | Toxic: >25 µg/L        |          |                     |            |             |        |         |

| Test Name                         | Ref. Range                       | Specimen | Method | Test<br>Frequency | Panel   | Pledge<br>TAT | Remarks |
|-----------------------------------|----------------------------------|----------|--------|-------------------|---------|---------------|---------|
| Testosterone                      | M(<1yr):<br>0.4 - 0.7 nmol/L     | S        | ECLIA  | Every<br>2 days   | Hormone | 2 days        |         |
|                                   | M(1-6yr):<br>0.1 - 1.1 nmol/L    |          |        |                   |         |               |         |
| Testosterone                      | M(7-12yr):<br>0.1 - 2.4 nmol/L   | S        | ECLIA  | Every<br>2 days   | Hormone | 2 days        |         |
|                                   | M(13-17yr):<br>1.0 - 38.5 nmol/L |          |        |                   |         |               |         |
|                                   | M(18-19yr):<br>8.6 - 29.0 nmol/L |          |        |                   |         |               |         |
|                                   | M(20-49yr):<br>8.6 - 29.0 nmol/L |          |        |                   |         |               |         |
|                                   | M(>50yr):<br>6.7 - 25.7 nmol/L   |          |        |                   |         |               |         |
|                                   | F(<1yr):<br>0.4 - 0.7 nmol/L     |          |        |                   |         |               |         |
|                                   | F(1-6yr):<br>0.1 - 1.1 nmol/L    |          |        |                   |         |               |         |
|                                   | F(7-12yr):<br>0.1 - 2.4 nmol/L   |          |        |                   |         |               |         |
|                                   | F(13-17yr):<br>1.0 - 38.5 nmol/L |          |        |                   |         |               |         |
|                                   | F(18-19yr):<br>0.3 - 1.7 nmol/L  |          |        |                   |         |               |         |
|                                   | F(20-49yr):<br>0.3 - 1.7 nmol/L  |          |        |                   |         |               |         |
|                                   | F(>50yr):<br>0.1 - 1.4 nmol/L    |          |        |                   |         |               |         |
| Thyroglobulin                     | >=21yr:<br>3.5 - 77.0 µg/L       | S        | ECLIA  | Every<br>2 days   | Thyroid | 2 days        |         |
| Thyroid stimulating hormone (TSH) | 0.27 - 4.20 mIU/L                | HP       | ECLIA  | Daily             | Thyroid | 24<br>hours   |         |

| Test Name   | Ref. Range                                 | Specimen    | Method                        | Test            | Panel          | Pledge      | Remarks             |
|---|--|-------------|-------------------------------|-----------------|----------------|-------------|---------------------|
|   |  |             |                               | Frequency       |                | TAT         |                     |
| Total iron binding capacity (TIBC)                          | 44.8 - 80.6 µmol/L                         | HP          | Calculated from transferrin   | On arrival      | Anaemic marker | 24<br>hours |                     |
| Total procollagen-type<br>1 N-terminal-propeptide<br>(P1NP) | (pre-menopause):<br>15 - 59 μg/L           | EDTA Plasma | ECLIA                         | Every<br>2 days | Bone marker    | 2 days      |                     |
| Total T3  | F<br>(Post-<br>menopause):<br>16 - 74 µg/L |             |                               |                 |                |             |                     |
| Total T3  | 0.54 - 2.96 nmol/L                         | S           | CMIA                          | Every<br>2 days | Hormone        | 2 days      |                     |
| Total T4  | 58 - 154 nmol/L                            | S           | CMIA                          | Every<br>2 days | Hormone        | 2 days      |                     |
| Transferrin   | 2.0 - 3.6 g/L                              | HP          | Immunoturbidimetric           | On arrival      | Anaemic marker | 24<br>hours |                     |
| Triglycerides   | Normal<br><1.69 mmol/L                     | HP          | Lipase/Glycerol<br>Kinase/GPO | On arrival      | Lipids         | 4<br>hours  | 12 hours<br>fasting |
|   | Borderline high:<br>1.69 - 2.25<br>mmol/L  |             |                               |                 |                |             |                     |
|   | High:<br>2.26 - 5.64<br>mmol/L             |             |                               |                 |                |             |                     |
|   | Very high:<br>>=5.65 mmol/L                |             |                               |                 |                |             |                     |
| Troponin I  | M: <0.0342 μg/L<br>F: <0.0156 μg/L         | HP          | CMIA                          | On arrival      | Cardiac marker | 2<br>hours  |                     |
| Troponin T  | <0.014 µg/L                                | HP          | ECLIA                         | On arrival      | Cardiac marker | 2<br>hours  |                     |
| Tryptase  | <11.0 µg/L                                 | S           | ImmunoCAP                     | Daily           | Tryptase       | 24<br>hours |                     |

| Test Name                             | Ref. Range                                   | Specimen | Method                           | Test<br>Frequency | Panel                  | Pledge<br>TAT | Remarks                                    |
|---------------------------------------|--|----------|----------------------------------|-------------------|------------------------|---------------|--|
| Urea                                  | 2.8 - 8.1 mmol/L                             | HP       | Enzymatic, Urease                | On arrival        | Renal                  | 4<br>hours    |  |
| Uric acid                             | M: 0.25 - 0.48<br>mmol/L                     | HP       | Enzymatic, Urease/<br>Peroxidase | On arrival        | Renal/Gout             | 4<br>hours    |  |
|                                       | F: 0.14 - 0.34<br>mmol/L                     |          |                                  |                   |                        |               |  |
| Urine albumin-to-<br>creatinine ratio | M: <1.92<br>mg/mmol                          | U        | Turbidimetry/Jaffe               | Daily             | Renal                  | 24<br>hours   |  |
|                                       | F: <2.83<br>mg/mmol<br>Jones N/A U           |          |                                  |                   |                        |               |  |
| Urine Bence Jones<br>protein          | N/A  | U        | Agarose gel electrophoresis      | Daily             | Paraprotein            | 5 days        | preferred<br>24 hr U, at<br>least 50<br>mL |
| Urine immunofixation                  | N/A  | U        | Agarose gel<br>electrophoresis   | Daily             | Paraprotein            | 5 days        | preferred<br>24 hr U, at<br>least 50<br>mL |
| Urine protein-to-<br>creatinine ratio | 18-83 years:<br><0.16 mg/mg                  | U        | Biuret/Jaffe                     | On arrival        | Renal                  | 24<br>hours   |  |
| Valproic acid                         | Therapeutic:<br>347 - 693 umol/L             | S        | Enzyme immunoassay               | On arrival        | Therapeutic drug level | 4<br>hours    |  |
|                                       | Toxic: >693<br>umol/L                        |          |                                  |                   |                        |               |  |
| Vancomycin                            | Therapeutic<br>(peak):<br>17.3 - 27.6 µmol/L | S        | KIMS                             | On arrival        | Therapeutic drug level | 4<br>hours    |  |
|                                       | (trough):<br>3.5 - 6.9 µmol/L                |          |                                  |                   |                        |               |  |
| Vitamin B12                           | Deficient:<br><150 pmol/L                    | HP       | ECLIA                            | Every<br>2 days   | Anaemic marker         | 2 days        |  |

| Test Name                          | Ref. Range                      | Specimen | Method                     | Test<br>Frequency | Panel                    | Pledge<br>TAT | Remarks |
|------------------------------------|---------------------------------|----------|----------------------------|-------------------|--------------------------|---------------|---------|
| Vitamin D (25-OH) total            | Deficient:<br><25 nmol/L        | HP       | ECLIA                      | Every<br>2 days   | Vitamin                  | 2 days        |         |
|                                    | Insufficient:<br>25 - 50 nmol/L |          |                            |                   |                          |               |         |
|                                    | Adequate:<br>50 - 250 nmol/L    |          |                            |                   |                          |               |         |
| >25                                | Potentially toxic: >250 nmol/L  |          |                            |                   |                          |               |         |
| 24 hr Urinary calcium              | 2.5 - 7.5 mmol/<br>day          | 24-hr U  | NM-BAPTA                   | Daily             | Parathyroid/Renal stones | 24<br>hours   |         |
| 24 hr Urinary creatinine           | M: 9 - 21<br>mmol/day           | 24-hr U  | Jaffe, Alk. Picrate        | Daily             | Renal                    | 24<br>hours   |         |
|                                    | F: 7 - 14 mmol/<br>day          |          |                            |                   |                          |               |         |
| 24 hr Urinary potassium            | 25 - 125 mmol/<br>day           | 24-hr U  | Indirect ISE               | Daily             | Renal                    | 24<br>hours   |         |
| 24 hr Urinary protein              | <0.14 g/day                     | 24-hr U  | Turbidimetry               | Daily             | Renal                    | 24<br>hours   |         |
| 24 hr Urinary sodium               | 40 - 220 mmol/<br>day           | 24-hr U  | Indirect ISE               | Daily             | Renal                    | 24<br>hours   |         |
| 24 hr Urinary inorganic phosphorus | 13 - 42 mmol/day                | 24-hr U  | Phosphomolybdate formation | Daily             | Renal                    | 24<br>hours   |         |
| 24 hr Urinary urea                 | <580 mmol/day                   | 24-hr U  | Enzymatic, Urease          | Daily             | Renal                    | 24<br>hours   |         |

#### Clinical Haematology (ext. 8795)

| Test Name                                | Ref. Range   | Specimen | Method                 | Test<br>Frequency | Panel       | Pledge<br>TAT |
|--|--|----------|------------------------|-------------------|-------------|---------------|
| Complete blood picture (CBP) Haemoglobin | Male:<br>13-17 g/dL<br>Female:<br>11.5-15.5g/dL              | EW       | Automated cell counter | On arrival        | Haematology | 2-4<br>hours  |
| RBC                                      | Male:<br>4.50-6.00 x 1012/L<br>Female:<br>3.70-5.20 x 1012/L |          |                        |                   |             |               |
| НСТ                                      | Male:<br>40.0 - 50.0 %<br>Female:<br>35.0 - 46.0 %           |          |                        |                   |             |               |
| MCV                                      | 80.0 - 98.0 fL   |          |                        |                   |             |               |
| MCH                                      | 27.0 - 33.0 pg   |          |                        |                   |             |               |
| MCHC                                     | 32.0 - 36.0 g/dL   |          |                        |                   |             |               |
| RDW                                      | 10.0 - 15.0 %  |          |                        |                   |             |               |
| WBC Count                                | 4.00 - 11.0 x 109/L  |          |                        |                   |             |               |
| Neutrophil                               | 70 - 8.00 x 109/L<br>40.0 - 75.0 %                           |          |                        |                   |             |               |
| Lymphocyte                               | 1.00 - 4.50 x 109/L<br>16.0 - 45.0 %                         |          |                        |                   |             |               |
| Monocyte                                 | 0.2 - 1.0 x 109/L<br>2.5 -13.0 %                             |          |                        |                   |             |               |
| Eosinophil                               | 0.0 - 0.5 x 109/L<br>0.0 - 6.5 %                             |          |                        |                   |             |               |
| Basophil                                 | 0.0 - 0.15 x 109/L<br>0.0 - 2.0 %                            |          |                        |                   |             |               |
| Platelet                                 | 150 - 400 x 109/L  |          |                        |                   |             |               |

#### Clinical Haematology (ext. 8795)

| Test Name  | Ref. Range  | Specimen           | Method                                    | Test<br>Frequency | Panel       | Pledge<br>TAT |
|--|---|--------------------|---|-------------------|-------------|---------------|
| Reticulocyte Count   | 32-135 x 109/L<br>0.2-2.0 %   | EW                 | Automated cell counter                    | On arrival        | Haematology | 2-4<br>hours  |
| Ret Hb Content   | 30.7-39.1 pg  | EW                 | Automated cell counter                    | On arrival        | Haematology | 2-4<br>hours  |
| Blood film review by<br>Hosp. Haematologist  | N/A   | EW/ Blood<br>Smear | Microscope                                | On arrival        | Haematology | 24<br>hours   |
| E.S.R.   | Male ≤60 yrs:<br>0 - 15 mm/hr<br>Male ≥60 yrs:<br>0 - 20 mm/hr<br>Female≤60 yrs:<br>0-20mm/hr<br>Female≥60 yrs:<br>0-30 mm/hr | EW                 | Modified Westergren<br>Automated          | On arrival        | Haematology | 2-4 hrs       |
| Haemoglobin pattern<br>(quantification of HbA2,<br>HbF, detection of Hb<br>variants) | HbA2: 2.2-3.3 %<br>HbF: <2.0 %  | EW                 | High Performance Liquid<br>Chromatography | Every<br>Thursday | Haematology | 1 week        |
| Malaria Parasites  | Negative  | EW                 | Microscopy                                | On arrival        | Haematology | 2-4<br>hours  |
| Malaria p.f./p.v.Antigen by immunoassay  | Negative  | EW                 | P.f (HRPII) / Pan (aldolase)              | On arrival        | Haematology | 2-4<br>hours  |
| Activated partial thromboplastin time  | 22.6 - 33.2 seconds   | С                  | Clotting assay                            | On arrival        | Haematology | 2-4<br>hours  |
| Prothrombin time (PT) & INR  | 10.0 - 13.0 seconds   | С                  | Clotting assay                            | On arrival        | Haematology | 2-4<br>hours  |
| Thrombin Time (TT)   | 16.3-19.2 seconds   | С                  | Clotting assay                            | On arrival        | Haematology | 2-4<br>hours  |

#### Clinical Haematology (ext. 8795)

| Test Name                                      | Ref. Range   | Specimen | Method                    | Test<br>Frequency            | Panel       | Pledge<br>TAT |
|--|--------------|----------|---------------------------|------------------------------|-------------|---------------|
| Fibrinogen<br>(Clauss Assay)                   | 1.6-3.7g/L   | С        | Von Clauss                | On arrival                   | Haematology | 2-4<br>hours  |
| Fibrinogen degradation products (FDP)          | <5μg/mL      | С        | Latex agglutination       | Every<br>Tuesday &<br>Friday | Haematology | 2-4<br>hours  |
| D-dimer (Quantitative)                         | <500µg/L FEU | С        | Immunoturbidimetric assay | On arrival                   | Haematology | 2-4<br>hours  |
| Antithrombin                                   | 79 - 120 %   | С        | Chromogenic assay         | Every<br>Friday              | Haematology | 1 week        |
| Activated Protein C<br>Resistance (APCR) ratio | 0.9 - 1.3    | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor II                                      | 70-150%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor V                                       | 70-150%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor VII                                     | 70-150%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor VIII                                    | 70-200%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor IX                                      | 70-120 %     | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor X                                       | 70-150%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor XI                                      | 60-150%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor XII                                     | 40-120%      | С        | Clotting assay            | Every<br>Friday              | Haematology | 1 week        |
| Factor XIII                                    | 50-120%      | С        | Chromogenic assay         | Every<br>Friday              | Haematology | 1 week        |

#### Clinical Haematology (ext. 8795)

| Test Name   | Ref. Range   | Specimen | Method                    | Test<br>Frequency | Panel       | Pledge<br>TAT |
|---|--|----------|---------------------------|-------------------|-------------|---------------|
| Lupus anticoagulant                                       | 0.8-1.2  | С        | Clotting assay            | Every<br>Friday   | Haematology | 1 week        |
| Protein C Activity  | 77-178%  | С        | Clotting assay            | Every<br>Friday   | Haematology | 1 week        |
| Free Protein S Ag   | Male:<br>67.5-139%<br>Female:<br>60-114%                                     | С        | Immunoturbidimetric assay | Every<br>Friday   | Haematology | 1 week        |
| Von Willebrand factor antigen                             | 50-160%  | С        | Immunoturbidimetric assay | Every<br>Friday   | Haematology | 1 week        |
| Von Willebrand factor<br>Activity                         | 52-181%  | С        | Immunoturbidimetric assay | Every<br>Friday   | Haematology | 1 week        |
| Heparin monitoring<br>(Anti-Xa Assay)                     | Therapeutic LMWH:<br>0.5-1.2 IU/mL<br>Prophylactic<br>LMWH:<br>0.2-0.5 IU/ml | С        | Chromogenic assay         | Every<br>Tuesday  | Haematology | 1 week        |
| Hemoclot Thrombin<br>Inhibitor (Dabigatran<br>monitoring) | N/A  | С        | Clotting assay            | Every<br>Tuesday  | Haematology | 1 week        |
| Rivaroxaban (Xarelto monitoring)                          | N/A  | С        | Chromogenic assay         | Every<br>Tuesday  | Haematology | 1 week        |
| Apixaban<br>(Eliquis monitoring)                          | N/A  | С        | Chromogenic assay         | Every<br>Tuesday  | Haematology | 1 week        |
| Edoxaban<br>(Lixiana monitoring)                          | N/A  | С        | Chromogenic assay         | Every<br>Tuesday  | Haematology | 1 week        |
| Bleeding Time<br>(Platelet function by<br>PFA-100)        | N/A  | CW&EW    | PFA-100                   | On arrival        | Haematology | 2-4<br>hours  |

#### Clinical Haematology (ext. 8795)

| Test Name                                    | Ref. Range | Specimen | Method                                | Test<br>Frequency | Panel       | Pledge<br>TAT |
|--|------------|----------|---------------------------------------|-------------------|-------------|---------------|
| VerifyNow Aspirin response                   | N/A        | CW&EW    | Turbidometric based optical detection | On arrival        | Haematology | 2-4<br>hours  |
| VerifyNow Plavix response                    | N/A        | CW&EW    | Turbidometric based optical detection | On arrival        | Haematology | 2-4<br>hours  |
| Bone Marrow Reporting by Hosp. Haematologist | N/A        | BM       | N/A                                   | On arrival        | Haematology | 2-4<br>hours  |
| Cytochemistry & Reporting                    | N/A        | BM/EW    | N/A                                   | On arrival        | Haematology | 4-6<br>hours  |
| Trephine Reporting by Hosp. Haematologist    | N/A        | BM       | N/A                                   | On arrival        | Haematology | 2 days        |

\*C: Citrated plasma

\*U: Urine

\*CW: Citrate Whole blood

\*MU: Morning urine
\*BM: Bone marrow

\*S: Serum

\*BF: Body fluid

\*EW: EDTA Whole blood

#### Clinical Microbiology (Ext. 8791)

| Test Name   | Ref. Range | Specimen                        | Method   | Test<br>Frequency   | Panel                           | Pledge<br>TAT                             |
|---|------------|---------------------------------|--|---------------------|---------------------------------|---|
| AFB Stain   | N/A        | All kinds                       | Kinyoun stain<br>Auramine O stain                            | Daily<br>On arrival | TB profile                      | Routine:<br>1 day<br>Urgent:<br>3-6 hours |
| Amoeba  | N/A        | Stool                           | Microscopy   | On arrival          | Stool                           | 1-2 days                                  |
| Anaerobic<br>Culture  | N/A        | All kinds                       | Culture medium inoculation                                   | On arrival          | Bacterial culture               | 5 days                                    |
| Blood Culture   | N/A        | Blood                           | Broth inoculation  | On arrival          | Bacterial culture               | 7 days                                    |
| Clostridium<br>difficile Culture                                      | N/A        | Stool                           | Selective medium inoculation                                 | On arrival          | Stool                           | 2 days                                    |
| Culture &<br>Sensitivity  | N/A        | All kinds                       | Culture medium inoculation/<br>Antibiotic disk diffusion     | On arrival          | Bacterial culture               | 2-3 days                                  |
| CPE Screen  | N/A        | Stool / Rectal<br>swab / others | Selective medium inoculation                                 | On arrival          | MDRO Screening                  | 2 days                                    |
| Fungus Culture  | N/A        | All kinds                       | Selective medium inoculation                                 | On arrival          | Fungal culture                  | 14 days                                   |
| Fungus Smear  | N/A        | All kinds                       | Lactophenol cotton blue stain<br>Gram's stain                | Daily<br>On arrival | Differential staining           | Routine:<br>1 day<br>Urgent:<br>2-6 hours |
| Gram Stain  | N/A        | All kinds                       | Gram's stain   | Daily<br>On arrival | Differential staining           | Routine:<br>1 day<br>Urgent:<br>2-6 hours |
| Group B Beta-<br>streptococcus<br>Screen<br>(GeneXpert) &<br>GBS C&ST | N/A        | Vaginal /<br>Rectal swab        | PCR/Selective medium inoculation / Antibiotic disk diffusion | On arrival          | Rapid Nucleic<br>Acid Detection | 4 hours                                   |

#### Clinical Microbiology (Ext. 8791)

| Test Name  | Ref. Range | Specimen            | Method   | Test<br>Frequency                | Panel                                  | Pledge<br>TAT |
|--|------------|---------------------|--|----------------------------------|--|---------------|
| H. pylori Culture<br>& Sensitivity                           | N/A        | Gastric biopsy      | Selective medium inoculation /<br>Antibiotic disk diffusion  | On arrival                       | Helicobacter                           | 7-10 days     |
| India Ink  | N/A        | CSF                 | India Ink Stain  | On arrival                       | Differential staining for Cryptococcus | 2 hours       |
| Microscopic<br>Examination of<br>Crystals                    | N/A        | Joint fluid         | Microscopic polarization examination                         | On arrival                       | Joint fluid                            | 1 day         |
| Microscopy for<br>Demodex                                    | N/A        | Eye lashes          | Microscopic examination                                      | Prior<br>arrangement<br>required | Microscopic examination                | 2 hours       |
| MRSA Screen  | N/A        | Nasal swab / others | Selective medium inoculation /<br>Antibiotic disk diffusion  | On arrival                       | MDRO Screening                         | 2 days        |
| MRSA Screen<br>(GeneXpert) &<br>MRSA C&ST                    | N/A        | Nasal swab / others | PCR/Selective medium inoculation / Antibiotic disk diffusion | On arrival                       | Rapid Nucleic<br>Acid Detection        | 4 hours       |
| MTB-Nucleic<br>Acid Detection                                | N/A        | All kinds           | PCR  | Daily                            | TB profile                             | 1 day         |
| MTB/RIF<br>resistance<br>(GeneXpert)                         | N/A        | Sputum              | PCR  | On arrival                       | Rapid Nucleic<br>Acid Detection        | 6 hours       |
| Mycoplasma<br>hominis &<br>Ureaplasma<br>urealyticum<br>C&ST | N/A        | Genital swab        | Strip inoculation  | On arrival                       | STD                                    | 2-3 days      |

#### Clinical Microbiology (Ext. 8791)

| Test Name             | Ref. Range  | Specimen               | Method  | Test<br>Frequency | Panel          | Pledge<br>TAT |
|-----------------------|---|------------------------|---|-------------------|----------------|---------------|
| Occult Blood          | Negative:<br><50 ng/mL<br>Borderline: 50-99<br>Positive: ≥100 | Stool                  | Fecal immunochemical test                       | On arrival        | Stool          | 8-16 hours    |
| Stool routine         | N/A   | Stool                  | Microscopic examination                         | On arrival        | Stool          | 8-16 hours    |
| Trichomonas & Monilia | N/A   | Genital Swab           | Microscopic examination                         | On arrival        | STD            | 2 days        |
| Urine routine         | N/A   | Urine                  | Automated urine chemistry & cell count analysis | On arrival        | Urine          | 2-4 hours     |
| Pregnancy test        | N/A   | Urine                  | Lateral flow assay                              | On arrival        | Urine          | 2 hours       |
| VRE Screen            | N/A   | Stool /<br>Rectal swab | Selective medium inoculation                    | On arrival        | MDRO Screening | 2 days        |

Note: For bacterial and fungal culture, a preliminary report will be issued once the pathogenic microorganism is isolated.

| Test Name                               | Ref. Range  | Specimen       | Method | Test<br>Frequency   | Panel      | Pledge TAT       | Remarks  |
|---|---|----------------|--------|---------------------|------------|------------------|--|
| ADAMTS 13 Antigen<br>& Auto-Antibody    | Antigen: Normal 0.32-0.73 (IU/mL) Antibody: Negative <15 (units/mL) Borderline: 15-20 Positive: >20 | Citrate plasma | ELISA  | Monthly             | Immunology | 1 month          | Freeze<br>double-spin<br>plasma at<br>-80°C if not<br>tested right<br>away |
| ADAMTS Activity                         | Normal: 70-160%   | Citrate plasma | FRET   | 1-2 times<br>a week | Immunology | 2-5 working days | Freeze<br>double-spin<br>plasma at<br>-80°C if not<br>tested right<br>away |
| ANCA                                    | Negative: <20<br>(Titre)<br>Positive: ≥20   | Serum          | IFA    | 2 times<br>a week   | Immunology | 4 working days   |  |
| ANCA-MPO &<br>ANCA-PR3                  | Normal:<br><20 (RU/mL)<br>Elevated: ≥20   | Serum          | ELISA  | 2 times<br>a week   | Immunology | 4 working days   |  |
| Anti-Cardiolipin<br>IgG & IgM           | IgG & IgM:<br>Negative:<br><12 (U/mL)<br>Elevated: ≥12  | Serum          | ELISA  | 2 times<br>a week   | Immunology | 4 working days   |  |
| Anti-CCP (cyclic citrullinated peptide) | Normal: <5 RU/mL<br>Elevated: ≥5  | Serum          | ELISA  | 2 times<br>a week   | Immunology | 4 working days   |  |
| Anti-ds DNA                             | Negative:<br><100 (IU/mL)<br>Positive: ≥100   | Serum          | ELISA  | 2 times<br>a week   | Immunology | 4 working days   |  |

#### Clinical Immunology (ext. 8796)

| Test Name  | Ref. Range  | Specimen | Method     | Test<br>Frequency  | Panel      | Pledge TAT          | Remarks |
|--|---|----------|------------|--|------------|---------------------|---------|
| Anti-ENA Profile by<br>ELISA (Ribosomal P<br>proteins, nRNP/Sm,<br>Sm, SS-A, SS-B, ScI-70,<br>Jo-1 & Centromeres)  | Negative: <1.0<br>Weak Positive:<br>≥1.0-2.0<br>Positive: >2.0-5.0<br>High Positive: >5.0 | Serum    | ELISA      | Weekly   | Immunology | 7 working days      |         |
| Anti-ENA Profile<br>by Immunoblot<br>(Mi-2, Ku, nRNP/<br>Sm, Sm, SS-A,Ro-52,<br>SS-B, ScI-70, PM-ScI,<br>Jo-1, CENP-B, PCNA,<br>dsDNA, Nucleosomes,<br>Histones, Rib P protein,<br>AMA, M2, DFS70) | N/A   | Serum    | Immunoblot | 2 times<br>a week  | Immunology | 4 working days      |         |
| Anti-Nuclear Antibody<br>(ANA)   | Negative: ≤40<br>(Titre)<br>Positive: >40   | Serum    | IFA        | Daily<br>(Except<br>Saturday,<br>Sundays<br>and<br>public<br>holidays) | Immunology | 2-4 working<br>days |         |
| Anti-PF4 IgG   | N/A   | Serum    | ELISA      | 2 times<br>a week  | Immunology | 4 working days      |         |
| Anti-PM-ScI IgG  | Normal:<br><20 (RU/mL)<br>Elevated: ≥20   | Serum    | ELISA      | Weekly   | Immunology | 7 working<br>days   |         |

| Test Name  | Ref. Range   | Specimen  | Method     | Test<br>Frequency | Panel      | Pledge TAT        | Remarks |
|--|--|-----------|------------|-------------------|------------|-------------------|---------|
| Anti-β2 Glycoprotein<br>1 IgG & IgM  | IgG & IgM:<br>Normal:<br><20 (RU/mL)<br>Elevated: ≥20                | Serum     | ELISA      | 2 times a<br>week | Immunology | 4 working days    |         |
| Aspergillus<br>Galactaomannan<br>Antigen   | Serum: Negative <0.5 Positive ≥0.5  BAL: Negative <1.0 Positive ≥1.0 | Serum/BAL | ELISA      | 3 times a<br>week | Immunology | 2 working<br>days |         |
| Autoimmune Inflammatory Myopathy (Anti-Mi-2α, Anti-Mi-2β, Anti-TiF1γ, Anti-MDA5, Anti-NXP2, Anti-SAE1, Anti-Ku, Anti-PM-ScI-100, Anti-PM-ScI-75, Anti-Jo-1, Anti-SRP, Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-Ro-52, Anti-cN-1A, Anti-HMGCR) | N/A  | Serum     | Immunoblot | 2 times a<br>week | Immunology | 4 working days    |         |

## Clinical Immunology (ext. 8796)

| Test Name   | Ref. Range   | Specimen | Method                 | Test<br>Frequency | Panel      | Pledge TAT       | Remarks |
|---|--|----------|------------------------|-------------------|------------|------------------|---------|
| Bacterial Antigen Screen (H.influenza b, Strep B, Pneumococcus, Meningococcus, E. coli) | N/A  | Serum    | Latex<br>agglutination | On arrival        | Immunology | 1 working<br>day |         |
| Bacterial Antigen Screen (H.influenza b, Strep B, Pneumococcus, Meningococcus, E. coli) | N/A  | CSF      | Latex<br>agglutination | On arrival        | Immunology | 3 hours          |         |
| Brucella<br>Agglutination Test  | N/A  | Serum    | Latex agglutination    | Daily             | Immunology | 2 working days   |         |
| Chlamydia<br>pneumoniae<br>Ab-lgG/lgM   | Negative: <0.8<br>Boderline: 0.8-1.0<br>Positive: >1.0 | Serum    | ELISA                  | 2 times<br>a week | Immunology | 4 working days   |         |
| Chlamydia<br>trachomatis<br>Ab-IgG  | Negative: <0.8<br>Boderline: 0.8-1.0<br>Positive: >1.0 | Serum    | ELISA                  | 2 times<br>a week | Immunology | 4 working days   |         |
| Cryptococcal<br>Antigen   | N/A  | CSF      | Lateral flow assay     | On arrival        | Immunology | 3 hours          |         |
| Cryptococcal<br>Antigen   | N/A  | Serum    | Lateral flow assay     | On arrival        | Immunology | 1 working<br>day |         |
| Dengue Virus Ab IgG,<br>IgM and NS1 Rapid<br>Test                                       | N/A  | Serum    | Lateral flow<br>assay  | On arrival        | Immunology | 4 hours          |         |

| Test Name                                     | Ref. Range   | Specimen | Method                | Test<br>Frequency   | Panel      | Pledge TAT        | Remarks |
|---|--|----------|-----------------------|---|------------|-------------------|---------|
| EBV Ab IgM & IgG for infectious mononucleosis | N/A  | Serum    | Immunoblot            | 3 times<br>a week   | Immunology | 4 working days    |         |
| EBV Ab-IgA                                    | Negative:<br>VCA: <10 (Titre)<br>EA: <5<br>Positive:<br>VCA: ≥10 (Titre)<br>EA: ≥5 | Serum    | IFA                   | 2 times<br>a week   | Immunology | 4 working<br>days |         |
| Entamoeba<br>histolytica Ab-IgG               | N/A  | Serum    | ELISA                 | 2 times a week  | Immunology | 4 working days    |         |
| H. pylori Ab-IgG                              | N/A  | Serum    | Lateral flow<br>assay | Daily<br>(Except<br>Sundays<br>and<br>public<br>holidays) | Immunology | 1 working<br>day  |         |
| H. pylori Antigen                             | N/A  | Stool    | Lateral flow<br>assay | Daily<br>(Except<br>Sundays<br>and<br>public<br>holidays) | Immunology | 1 working<br>day  |         |
| HSV 1 Specific Ab-IgG                         | Negative: <0.8<br>(Index value)<br>Equivocal: 0.8-1.0<br>Positive: >1.0            | Serum    | ELISA                 | 2 times<br>a week   | Immunology | 4 working days    |         |

|  |   |          |                       |  | Om noar min | (10.10.09)  | 0,111 0, 70) |
|--|---|----------|-----------------------|--|-------------|---|--------------|
| Test Name  | Ref. Range  | Specimen | Method                | Test<br>Frequency  | Panel       | Pledge TAT  | Remarks      |
| HSV 2 Specific Ab-IgG  | Negative: <0.8<br>(Index value)<br>Equivocal: 0.8-1.0<br>Positive: >1.0 | Serum    | ELISA                 | 2 times a<br>week  | Immunology  | 4 working days  |              |
| Legionella Urinary<br>Antigen  | N/A   | Urine    | Lateral flow assay    | On arrival   | Immunology  | 4 hours   |              |
| Measles Ab-IgG   | N/A   | Serum    | Enzyme<br>immunoassay | 3 times<br>a week  | Immunology  | 4 working<br>days<br>(6 hours for<br>pregnancy<br>case) |              |
| Monospot Test<br>(Heterophile Ab-IgM)  | N/A   | Serum    | Lateral flow assay    | Daily  | Immunology  | 1 working<br>day  |              |
| Mycoplasma<br>pneumoniae Ab-IgM  | N/A   | Serum    | ELISA                 | Daily<br>(Except<br>Saturday,<br>Sundays<br>and<br>public<br>holidays) | Immunology  | 1 working<br>day  |              |
| Parasite Antigen<br>Screen<br>(Giardia. Entamoeba<br>histolytica,<br>Crytosporidium) | N/A   | Stool    | Lateral flow<br>assay | Daily<br>(Except<br>Sundays<br>and<br>public<br>holidays)              | Immunology  | 1 working<br>day  |              |
| Parvovirus B19 Ab-IgG  | Negative:<br><64 (Titre)<br>Positive: ≥64                               | Serum    | IFA                   | 2 times<br>a week  | Immunology  | 4 working days  |              |

| Test Name                                   | Ref. Range  | Specimen  | Method     | Test<br>Frequency  | Panel      | Pledge TAT         | Remarks |
|---|---|---|------------|--|------------|--------------------|---------|
| Parvovirus B19 Ab-IgM                       | Negative:<br><16 (Titre)<br>Positive: ≥16                                       | Serum   | IFA        | 2 times<br>a week  | Immunology | 4 working<br>days  |         |
| QuantiFeron-TB Gold                         | Negative:<br><0.35 (IU/mL)<br>Borderline:<br>≥0.35 and <0.70<br>Positive: ≥0.70 | Plasma<br>(special tubes<br>required,<br>provided by lab) | ELISA      | 2 times<br>a week  | Immunology | 4 working<br>days  |         |
| Rapid Influenza A & B<br>and RSV Screen     | N/A   | Nasopharyngeal<br>swab/<br>Nasopharyngeal<br>aspirate     | PCR        | On arrival   | Immunology | 2 hours            |         |
| SARS-CoV-2<br>Neutralizing<br>Antibody Test | N/A   | Serum   | CLIA       | Daily<br>(Except<br>Sundays<br>and<br>public<br>holidays)  | Immunology | 1-2 working<br>day |         |
| Seminal Fluid Routine<br>Analysis           | N/A   | Semen   | Microscopy | On arrival<br>(service<br>time:<br>08:00-<br>15:00<br>except<br>Sunday<br>and<br>public<br>holidays) | Immunology | 1 working<br>day   |         |

#### Clinical Immunology (ext. 8796)

| Test Name   | Ref. Range | Specimen    | Method                 | Test<br>Frequency   | Panel      | Pledge TAT       | Remarks |
|---|------------|-------------|------------------------|---|------------|------------------|---------|
| Streptococcus pneumoniae Antigen  | N/A        | Urine       | Lateral flow assay     | On arrival  | Immunology | 4 hours          |         |
| Streptococcus<br>pyogenes Group A<br>Antigen  | N/A        | Throat swab | Lateral flow assay     | On arrival  | Immunology | 2 hours          |         |
| Strongyloides Ab-IgG  | N/A        | Serum       | ELISA                  | 2 times<br>a week   | Immunology | 4 working days   |         |
| Syhpilis RPR  | N/A        | Serum       | Latex<br>agglutination | Daily<br>(Except<br>Sundays<br>and<br>public<br>holidays) | Immunology | 1 working<br>day |         |
| Syphilis VDRL   | N/A        | CSF         | Latex agglutination    | On arrival  | Immunology | 4 hours          |         |
| Systemic Sclerosis<br>Profile<br>(Anti-Scl-70,<br>Anti-CENP A,<br>Anti-CENP B,<br>Anti-RP11, Anti-RP155,<br>Anti-Fibrillarin,<br>Anti-NOR90,<br>Anti-Th/To,<br>Anti-PM-Scl-100,<br>Anti-PM-Scl-75,<br>Anti-Ku, Anti-PDGFR,<br>Anti-Ro-52) | N/A        | Serum       | Immunoblot             | 2 times<br>a week   | Immunology | 4 working days   |         |

| Test Name                     | Ref. Range   | Specimen | Method                 | Test<br>Frequency | Panel      | Pledge TAT  | Remarks |
|-------------------------------|--|----------|------------------------|-------------------|------------|---|---------|
| T.P.P.A. for Syphilis         | N/A  | Serum    | Latex<br>agglutination | 2 times<br>a week | Immunology | 4 working<br>days<br>(6 hours for<br>pregnancy<br>case) |         |
| TPO Antibodies                | Negative:<br><50 (IU/mL)<br>Positive:<br>≥50 (IU/mL) | Serum    | ELISA                  | 2 times<br>a week | Immunology | 4 working days  |         |
| TSH Receptor Ab-IgG           | Normal:<br><1 (IU/mL)<br>Elevated:<br>≥1 (IU/mL)     | Serum    | ELISA                  | 2 times<br>a week | Immunology | 4 working days  |         |
| Varicella Zoster Virus<br>IgG | N/A  | Serum    | Enzyme<br>immunoassay  | 3 times<br>a week | Immunology | 4 working<br>days<br>(6 hours for<br>pregnancy<br>case) |         |
| Weil-Felix Test               | N/A  | Serum    | Latex agglutination    | Daily             | Immunology | 2 working days  |         |
| Widal Test                    | N/A  | Serum    | Latex agglutination    | Daily             | Immunology | 2 working days  |         |

| Test Name  | Ref. Range   | Specimen      | Method                     | Test Frequency | TAT (upon arrival of the specimen) | Panel            |
|--|--|---------------|----------------------------|----------------|------------------------------------|------------------|
| CSF routine analysis<br>(WBC, D/C, RBC, Glucose,<br>Protein)               | MNC <5/uL<br>Glucose:<br>Protein:  | CSF           | Microscopic examination    | On arrival     | 2 hours                            | CSF              |
| Pleural fluid routine analysis<br>(pH, WBC, D/C, RBC, Glucose,<br>Protein) | Exudate:<br>WBC >1000/uL<br>RBC >1000/uL<br>Transudate:<br>WBC <1000/uL<br>RBC <1000/uL<br>Glucose:<br>Protein:<br>pH: >7.64 | Pleural fluid | Microscopic<br>examination | On arrival     | 2-4 hours                          | Pleural fluid    |
| Ascitic fluid routine analysis<br>(pH, WBC, D/C, RBC, Glucose,<br>Protein) | Peritonitis:<br>WBC >500/uL<br>Glucose:<br>Protein:<br>pH: >7.36   | Ascitic fluid | Microscopic examination    | On arrival     | 2-4 hours                          | Ascitic fluid    |
| Joint fluid analysis (WBC, RBC)  | WBC <200/uL<br>Septic arthritis<br>≥50000/uL   | Joint fluid   | Microscopic examination    | On arrival     | 2-4 hours                          | Joint fluid      |
| Other body fluid analysis (pH, WBC, D/C, RBC)                              | N/A  | Body fluid    | Microscopic examination    | On arrival     | 2-4 hours                          | Other body fluid |

| Test Name  | Ref. Range | Specimen      | Test Frequency                   | Panel  | Pledge TAT   |
|--|------------|---------------|----------------------------------|--------|--|
| Hematopoietic Progenitor Cells (Apheresis) Processing and Cryopreservation | N/A        | Fresh *HPC(A) | Prior<br>arrangement<br>required | HPC(A) | 2 days<br>(preliminary<br>report)<br>14 days<br>(final report) |
| Hematopoietic Progenitor Cells (Apheresis)<br>Thawing                      | N/A        | Frozen HPC(A) | Prior<br>arrangement<br>required | HPC(A) | 2 days<br>(preliminary<br>report)<br>14 days<br>(final report) |

<sup>\*</sup>HPC(A): Hematopoietic Progenitor Cells (Apheresis)

| Flow Cytometry (ex | xt. 8412) |
|--------------------|-----------|

|   |  |           |                |                                  | Tiow Cylonic   | Olly (CXI. 0412) |
|---|--|-----------|----------------|----------------------------------|----------------|------------------|
| Test Name   | Ref. Range   | Specimen* | Method         | Test Frequency                   | Panel          | Pledge TAT       |
| Immunophenotyping I                                     | By Flow Cytometry  |           |                |                                  |                |                  |
| CD34 enumeration  | N/A  | EW        | Flow Cytometry | Prior<br>arrangement<br>required | Flow Cytometry | 6 hours          |
| Lymphocyte subsets<br>study including CD4<br>cell count | CD3+T cells: 56.3 - 86.0 % 764 - 2620 cells/µL CD3+/CD4+T cells: 25.2 - 53.0 % 354 - 1526 cells/µL CD3+/CD8+T cells: 17.9 - 46.0 % 318 - 1457 cells/µL CD19+ B cells: 6.2 - 19.2 % 103 - 666 cells/µL CD3-CD56+ NK cells: 6.6 - 28.6 % 89 - 621 cells/µL | EW        | Flow Cytometry | Daily                            | Flow Cytometry | 2 days           |
| Leukaemia and<br>lymphoma<br>Immunophenotyping          | N/A  | EW/BM/BF  | Flow Cytometry | Daily                            | Flow Cytometry | 2 days           |
| Minimal residual disease testing                        | <0.01% of MRD cells in all WBCs  | EW/BM     | Flow Cytometry | Daily                            | Flow Cytometry | 2 days           |
| Red cell study  |  |           |                |                                  |                |                  |
| PNH analysis  | <1% of PNH clones detected   | EW        | Flow Cytometry | Daily                            | Flow Cytometry | 2 days           |
| EMA binding test  | <20% reduction of<br>mean florescence<br>intensity from controls   | EW        | Flow Cytometry | Daily                            | Flow Cytometry | 2 days           |

|                         |                     |           |                |                | - /            | 311 y (37111 3 1 1 2 |  |
|-------------------------|---------------------|-----------|----------------|----------------|----------------|----------------------|--|
| Test Name               | Ref. Range          | Specimen* | Method         | Test Frequency | Panel          | Pledge TAT           |  |
| Fetal red cells in      | N/A                 | EW        | Flow Cytometry | Daily          | Flow Cytometry | 2 days               |  |
| maternal circulation    |                     |           |                |                |                |                      |  |
| Platelet study          |                     |           |                |                |                |                      |  |
| GPIIb/IIIa and          | Normal expression   | EW & C    | Flow Cytometry | Daily          | Flow Cytometry | 2 days               |  |
| GP1b/V/IX detection     | of CD41, CD42b and  |           |                |                |                |                      |  |
|                         | CD61                |           |                |                |                |                      |  |
| Basophil activation tes | t                   |           |                |                |                |                      |  |
| Autologous serum        | <5% CD63+/CD203c in | EW & S    | Flow Cytometry | Daily          | Flow Cytometry | 1 day                |  |
| PEG                     | basophils           |           |                |                |                |                      |  |

\*EW: EDTA Whole blood \*BM: Bone marrow \*BF: Body fluid

\*C: Citrated plasma \*S: Serum

#### Sleep Test (ext. 8794)

| Test Name         | Test Frequency             | Pledge TAT            | Remarks                            |
|-------------------|----------------------------|-----------------------|------------------------------------|
| Polysomnography   | Prior arrangement required | Within 3 working days | Overnight hospitalisation required |
| Auto C-PAP        | Prior arrangement required | 1 working day         | Overnight hospitalisation required |
| WATCH-PAT 100     | Prior arrangement required | 1 working day         | Overnight hospitalisation required |
| Oximetry          | Prior arrangement required | 1 working day         | Overnight hospitalisation required |
| TcCO <sub>2</sub> | Prior arrangement required | 1 working day         | Overnight hospitalisation required |
| SleepView         | Prior arrangement required | Within 3 working days | Home Sleep Test                    |
|                   |                            |                       |                                    |

| Histopathology (ext. 8839) |
|----------------------------|
|----------------------------|

| Test Name                                     | Specimen   | Storage & Transport  | Pledged TAT  | Notes                                      |
|---|--|--|--|--|
| Biopsy (Routine)                              | Tissue   | Fix in 10% buffered formalin*  | 1-3 working day<br>Large specimen may<br>take longer |  |
| Breast Cancer Markers<br>(ER; PR; Ki67; Her2) | 1.Tissue OR     2.Paraffin tissue block     OR     3.Tissue section on     charged/ coated     slide | Fix in 10% buffered formalin*  | 1-5 working days                                     |  |
| Consultation and<br>Review                    | Stained slide / paraffin tissue block  |  | 1-3 working days                                     | Slides or blocks returned if requested     |
| Electron Microscopy<br>(EM)                   | Tissue   | Fresh tissue.<br>Store and transport at 4°C  | Send-out test  | Please contact Lab for further information |
| Immunofluorescence (IF)                       | FRESH tissue   | Fresh tissue.<br>Store and transport at 4°C<br>(DO NOT FREEZE)   | Send-out test  | Please contact Lab for further information |
| Immunohistochemical<br>staining (IHC)         | 1.Tissue OR     2.Paraffin tissue block     OR     3.Tissue section on     charged/coated     slide  | Fix tissue in 10% buffered formalin*   | 1-5 working days                                     | Please contact Lab for further information |
| Muscle Biopsy                                 | Fresh muscle tissue  | <ul> <li>Enzyme studies: Fresh tissue</li> <li>Routine Histology: Fix in 10% buffered formalin*</li> </ul> | Send-out test  | Please contact Lab for further information |

| Test Name        | Specimen  | Storage & Transport  | Pledged TAT       | Notes                                      |
|------------------|---|--|-------------------|--|
| Renal Biopsy     | Fresh renal tissue  | <ul> <li>EM: Fresh tissue</li> <li>Routine Histology: Fix in<br/>10% buffered formalin*</li> </ul>   | EM: Send-out test | Please contact Lab for further information |
| Skin Biopsy      | Fresh skin tissue   | <ul> <li>IF: Fresh tissue. Store<br/>and transport at 4°C<br/>(DO NOT FREEZE)</li> <li>Routine Histology: Fix in<br/>10% buffered formalin*</li> </ul> | IF: Send-out test | Please contact Lab for further information |
| Special staining | 1.Tissue OR 2.Paraffin tissue block OR 3.Tissue section on charged/coated slide | Fix tissue in 10% buffered formalin*   | 1-3 working days  |  |

- 1. Office hours: 8am-6pm (Mon-Fri); 8am-1pm (Saturday); Closed on Saturday afternoon, Sunday & public holiday
- 2. For fresh specimen, please send to Lab ASAP.
- 3. \*Please contact Lab for the issue of formalin-containing bottles.

|   |   |   | Cylology C     | yriaccological (cxi. 0007)   |
|---|---|---|----------------|--|
| Test Name   | Specimen  | Storage & Transport                     | Pledged TAT    | Notes  |
| Pap smear<br>(BD SurePath Liquid-<br>based Pap Test)            | Brushed endocervical /<br>vaginal cells placed into the<br>BD SurePath collection vial with<br>preservation fluid           | Store and transport at room temperature | 5 working days | Please contact Lab for issue of BD SurePath collection vial (vial and brush)     Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history                                |
| Pap smear<br>(Conventional<br>method)                           | Brushed endocervical / vaginal<br>cells smeared on a microscopic<br>glass slide and fixed<br>immediately with cytofix spray | Store and transport at room temperature | 5 working days | Please contact Lab for issue of cytofix spray     Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history   |
| Human Papilloma Virus<br>(HPV)<br>- HPV PCR<br>- HPV Genotyping | Cervical cells from cervix<br>preserved in BD SurePath<br>collection vial   | Store and transport at room temperature | 5 working days | <ul> <li>3. Please contact Lab for issue of BD SurePath collection vial (vial and brush)</li> <li>4. Clinical information must include age, date of last menstrual period (LMP) and any relevant gynaecological history</li> </ul> |

Office hours: 8am-6pm (Mon-Fri); 8am-1pm (Saturday); Closed on Saturday afternoon, Sunday & public holiday

|                                      |  | Cytology – Non-   | gynaecologic        | al (ext. 8839)  |
|--------------------------------------|--|---|---------------------|---|
| Test Name                            | Specimen   | Storage & Transport   | Pledged TAT         | Notes   |
| Body cavity fluid for cytology       | Peritoneal, pelvic, pleural,<br>thoracic cavity and chest fluid  | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul>   | 1-3 working<br>days |   |
| Bronchial-alveolar<br>lavage         | Lavage from bronchio-alveolar spaces   | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul>   | 1-3 working<br>days |   |
| Bronchial washing                    | 10 ml. of warm sterile buffered<br>saline washing of cells washed<br>from the bronchi through a<br>fibreoptic bronchoscope | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul>   | 1-3 working<br>days |   |
| Brushing<br>(bronchial, CBD,<br>etc) | Cellular material obtained<br>by brushing and swiped on<br>microscopic slides  | <ul> <li>Fix smear/ slide IMMEDIATELY in a container of 95% alcohol or using Cytospray.</li> <li>Keep brush in a separate bottle filled with 50% alcohol.</li> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.</li> </ul> | 1-3 working<br>days | Do not<br>discard brush<br>as there may<br>be residual<br>cells useful for<br>diagnosis |
| Cerebro-spinal<br>fluid (CSF)        | Fluid drained from lumbar puncture or brain ventricles   | <ul> <li>Urgent transport to Lab is essential as the cells degenerate rapidly.</li> <li>After office hours, store in 4°C refrigerator (DO NOT FREEZE) and then deliver to Lab as soon as possible.</li> </ul>   | 1-3 working<br>days |   |
| Fine Needle<br>aspiration (FNA)      | Materials collected by fine<br>needle aspiration and spread<br>on slides   | <ul> <li>Fix slides IMMEDIATELY in a container of 95% alcohol or using Cytospray.</li> <li>Any residual material in the needle or syringe may be rinsed into FNA bottle. Refrigerate in 4°C if the specimen without fixative</li> </ul>   | 1-3 working<br>days | Please<br>contact Lab<br>for the issue<br>of FNA fixative-<br>containing<br>bottles     |

#### Cytology - Non-gynaecological (ext. 8839)

| Test Name             | Specimen                          | Storage & Transport   | Pledged TAT         | Notes                 |
|-----------------------|-----------------------------------|---|---------------------|-----------------------|
| Peritoneal<br>washing | Washings from peritoneum          | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul> | 1-3 working<br>days |                       |
| Sputum                | Early morning "deep cough" sputum | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul> | 1-3 working<br>days | Use sterile container |
| Urine                 | Voided urine                      | <ul> <li>Deliver to Lab immediately.</li> <li>After office hours, store in 4°C refrigerator<br/>(DO NOT FREEZE) and then deliver to Lab as<br/>soon as possible.</li> </ul> | 1-3 working<br>days |                       |

Office hours: 8am-6pm (Mon-Fri); 8am-1pm (Saturday); Closed on Saturday afternoon, Sunday & public holiday

#### Frozen Section (ext. 8839)

| Test Name       | Specimen         | Storage & Transport | Test                       | Pledged TAT   |
|-----------------|------------------|---------------------|----------------------------|---|
| Biopsy (Urgent  | Small tissue     | Fresh tissue or fix | Preliminary result will be | 1. Please deliver the specimen to lab on or before 11am |
| quick section   | (tissue size not | in 10% buffered     | given on or before 6pm     | 2. Urgent quick section will be arranged at 50%         |
| by rapid tissue | larger than      | formalin*           | within the same day        | additional charge                                       |
| processing)     | 0.5cm)           |                     |                            | 3. Full report: 1-3 working days                        |
| Frozen section  | Fresh tissue     | Fresh. DO NOT FIX   | 30 minutes                 | 1. Full report: 1-3 working days                        |
|                 |                  | IN FORMALIN.        | (verbal result)            | 2. For large specimen issue of full report may take     |
|                 |                  |                     |                            | longer  |

- 1. Office hours: 8am-6pm (Mon-Fri); 8am-1pm (Saturday); Closed on Saturday afternoon, Sunday & public holiday
- 2. Frozen section can be pre-arranged outside office hours at double charge. Advanced booking is preferred to guarantee manpower availability.
- 3. For fresh specimen, please send to Lab ASAP.
- 4. \*Please contact Lab for the issue of formalin-containing bottles.

#### MOLECULAR PATHOLOGY DIVISION

Infectious Disease (ext. 8779)

| Test Name                          | Ref.  | Specimen                         | Method   | Test              | Panel                             | Pledge TAT          | Remarks |
|------------------------------------|-------|----------------------------------|--|-------------------|-----------------------------------|---------------------|---------|
| EDV / DATA                         | Range | EW                               | Our and the dive   | Frequency         | Vivo asia, the survey surtice     | 2. F. continue      | ì       |
| EBV DNA                            | N/A   | EW                               | Quantitative   | 2 times           | Viremia, therapeutic              | 3-5 working         |         |
| Quantitative PCR                   |       |                                  | real-time PCR  | a week            | monitoring                        | days                |         |
| HBV DNA<br>Quantitative PCR        | N/A   | EW                               | Quantitative real-time PCR                                   | 2 times<br>a week | Viremia, therapeutic monitoring   | 3-5 working days    |         |
| CMV DNA<br>Quantitative PCR        | N/A   | EW                               | Quantitative real-time PCR                                   | On arrival        | Viremia, therapeutic monitoring   | 1-3 working days    |         |
| HIV RNA<br>Quantitative RT-PCR     | N/A   | EW                               | Quantitative real-time PCR                                   | 2 times<br>a week | Viremia, therapeutic monitoring   | 3-5 working<br>days |         |
| HCV RNA<br>Quantitative RT-PCR     | N/A   | EW                               | Quantitative real-time PCR                                   | 2 times<br>a week | Viremia, therapeutic monitoring   | 3-5 working days    |         |
| HBV YMDD Mutation                  | N/A   | EW                               | PCR & sequencing   | On arrival        | Viral resistance                  | 7 working days      |         |
| HBV ADV and ETV<br>Drug Resistance | N/A   | EW                               | PCR & sequencing   | On arrival        | Viral resistance                  | 7 working days      |         |
| HCV RNA<br>Genotyping              | N/A   | EW                               | RT-PCR & sequencing  | On arrival        | Viral resistance                  | 7 working days      |         |
| High-Risk HPV DNA<br>PCR           | N/A   | Autocyte,<br>ThinPrep,<br>others | Real-time PCR  | 2 times<br>a week | Cervical screening, HPV infection | 3-5 working days    |         |
| HPV DNA<br>Genotyping              | N/A   | Autocyte,<br>ThinPrep,<br>others | Real-time PCR<br>& next-/ third-<br>generation<br>sequencing | 2 times<br>a week | Cervical screening, HPV infection | 3-5 working<br>days |         |
| Chlamydia<br>trachomatis PCR       | N/A   | Genital swab, urine              | Real-time PCR  | On arrival        | STD screening                     | 2-4 working days    |         |
| Neisseria<br>gonorrhoeae PCR       | N/A   | Genital swab, urine              | Real-time PCR  | On arrival        | STD screening                     | 2-4 working days    |         |

|  |               |                       | Intectious Disease (ext                |                   |   |                     |   |  |
|--|---------------|-----------------------|--|-------------------|---|---------------------|---|--|
| Test Name  | Ref.<br>Range | Specimen              | Method                                 | Test<br>Frequency | Panel   | Pledge TAT          | Remarks   |  |
| Real-time Reverse<br>Transcription PCR for<br>SARS-CoV-2                   | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | SARS-CoV-2 infection                            | 1-2 working<br>days |   |  |
| Respiratory<br>Pathogen Panel by<br>Multiplex PCR                          | N/A           | Respiratory specimens | Real-time<br>PCR                       | On arrival        | Respiratory tract infection (bacterial & viral) | 1-2 working<br>days |   |  |
| Pneumonia Panel<br>by Multiplex PCR  | N/A           | Respiratory specimens | Real-time<br>PCR                       | On arrival        | Pneumonia<br>(bacterial & viral)                | 1-2 working days    |   |  |
| Real-time PCR<br>detection for<br>Influenza A,<br>H1N1pdm09, H3N2          | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | Influenza                                       | 1-2 working<br>days |   |  |
| Real-time PCR<br>detection for<br>Influenza A,<br>H1N1pdm09, H3N2,<br>H5N1 | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | Influenza                                       | 1-2 working<br>days | Please consult<br>our Clinical<br>Microbiologists/<br>Infection Control<br>Unit |  |
| Real-time PCR<br>detection for<br>Influenza B Virus                        | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | Influenza                                       | 1-2 working<br>days |   |  |
| Macrolide-Resistant<br>Mycoplasma<br>pneumoniae PCR                        | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | Atypical pneumonia                              | 2-4 working<br>days |   |  |
| Pneumocystis<br>jirovecii PCR  | N/A           | Respiratory specimens | Semi-<br>quantitative<br>real-time PCR | On arrival        | PCP pneumonia                                   | 2-4 working<br>days |   |  |
| Measles virus PCR  | N/A           | Respiratory specimens | Real-time<br>RT-PCR                    | On arrival        | Measles   | 2-4 working days    |   |  |

| Test Name   | Ref.<br>Range | Specimen         | Method                                    | Test<br>Frequency | Panel                               | Pledge TAT          | Remarks  |
|---|---------------|------------------|---|-------------------|-------------------------------------|---------------------|--|
| Enteric Pathogens<br>Detection by<br>Multiplex PCR                    | N/A           | Stool            | Real-time<br>RT-PCR                       | On arrival        | Gastroenteritis                     | 1-2 working<br>days |  |
| Viral Enteric<br>Pathogens PCR<br>(Norovirus &<br>Rotavirus)          | N/A           | Stool            | Real-time<br>RT-PCR                       | On arrival        | Gastroenteritis                     | 1-2 working<br>days |  |
| Clostridium difficile Toxin PCR                                       | N/A           | Stool            | Real-time<br>RT-PCR                       | On arrival        | Gastroenteritis                     | 1-3 working days    |  |
| Meningitis/<br>Encephalitis<br>Pathogen Detection<br>by Multiplex PCR | N/A           | CSF              | Real-time<br>RT-PCR                       | On arrival        | Meningitis/ encephalitis            | 1-2 working<br>days |  |
| Mosquito-borne<br>Pathogen Detection<br>by Multiplex PCR              | N/A           | Clotted<br>Blood | RT-PCR &<br>Microsphere-<br>based assay   | On arrival        | Mosquito-borne disease              | 3-5 working<br>days |  |
| Pathogen identification by direct sequencing                          | N/A           | Varies           | Next-/ third-<br>generation<br>sequencing | On arrival        | Targeted/ non-targeted metagenomics | 7 working days      | Please Consu<br>our Clinical<br>Microbiologist |

#### Molecular Haematopathology (ext. 8779)

| Test Name  | Ref.<br>Range | Specimen             | Method   | Test<br>Frequency | Panel                      | Pledge TAT          | Remarks |
|--|---------------|----------------------|--|-------------------|----------------------------|---------------------|---------|
| Myeloid Panel by<br>NGS                            | N/A           | EW, BM               | NGS  | once a<br>week    | Myeloid Leukemia           | 1 month             |         |
| Myeloid Panel +<br>Rapid Aneuploidy<br>Screen      | N/A           | EW, BM               | NGS  | once a<br>week    | Myeloid Leukemia           | 1 month             |         |
| Fusion Panel by<br>NGS                             | N/A           | EW, BM               | NGS  | once a<br>week    | Haematological<br>neoplasm | 1 month             |         |
| Rapid Aneuploidy<br>Screen                         | N/A           | EW, BM               | NGS  | once a<br>week    | Haematological<br>neoplasm | 7-10 working days   |         |
| MRD Single Variant (by NGS)                        | N/A           | EW, BM               | NGS  | once a<br>week    | Haematological<br>neoplasm | 2-4 weeks           |         |
| Karyotyping  | N/A           | EW, Heparin<br>blood | Karyotyping  | On arrival        | Cytogenetics               | 7-10 working days   |         |
| RUNX1::RUNX1T1<br>RT-PCR - t(8;21)                 | N/A           | EW, BM               | Conventional<br>RT-PCR                               | On arrival        | Acute Myeloid Leukemia     | 2-4 working days    |         |
| RUNX1::RUNX1T1<br>quantitative RT-PCR<br>- t(8;21) | N/A           | EW, BM               | Real-time<br>quantitative<br>RT-PCR                  | once a<br>week    | Acute Myeloid Leukemia     | 7 working days      |         |
| FLT3-ITD & TKD<br>Mutation                         | N/A           | EW, BM               | PCR + Fragment<br>Analysis<br>/ Sanger<br>sequencing | On arrival        | Acute Myeloid Leukemia     | 2-4 working days    |         |
| NPM1 exon 12<br>Mutation                           | N/A           | EW, BM               | PCR + Fragment<br>Analysis<br>/ Sanger<br>sequencing | On arrival        | Acute Myeloid Leukemia     | 2-4 working<br>days |         |
| CBFB/MYH11<br>(inv 16) RT-PCR                      | N/A           | EW, BM               | Conventional<br>RT-PCR                               | On arrival        | Acute Myeloid Leukemia     | 2-4 working<br>days |         |

#### Molecular Haematopathology (ext. 8779)

| Test Name  | Ref.<br>Range | Specimen | Method                              | Test<br>Frequency | Panel  | Pledge TAT        | Remarks                    |
|--|---------------|----------|-------------------------------------|-------------------|--|-------------------|----------------------------|
| CBFB::MYH11 Type A quantitative RT-PCR               | N/A           | EW, BM   | Real-time<br>quantitative<br>RT-PCR | once a<br>week    | Acute Myeloid Leukemia   | 7 working days    |                            |
| IDH1 and IDH2<br>hotspots Mutation                   | N/A           | EW, BM   | PCR + Sanger sequencing             | On arrival        | Acute Myeloid Leukemia   | 2-4 working days  |                            |
| IDH1 R132 Mutation                                   | N/A           | EW, BM   | PCR + Sanger sequencing             | On arrival        | Acute Myeloid Leukemia   | 2-4 working days  |                            |
| IDH2 R140 & R172<br>Mutation                         | N/A           | EW, BM   | PCR + Sanger sequencing             | On arrival        | Acute Myeloid Leukemia   | 2-4 working days  |                            |
| CEBPA Mutation                                       | N/A           | EW, BM   | PCR + Sanger sequencing             | On arrival        | Acute Myeloid Leukemia   | 3-5 working days  |                            |
| KIT exon 17 D816V<br>Mutation                        | N/A           | EW, BM   | PCR + Sanger<br>sequencing          | On arrival        | Acute Myeloid Leukemia<br>Myeloid and Lymphoid<br>Neoplasms with<br>eosinophilia | 2-4 working days  |                            |
| MRD Single Variant (by ddPCR)                        | N/A           | EW, BM   | ddPCR                               | On arrival        | Haematological neoplasm  | 7-10 working days | (2-3 months for new assay) |
| BCR::ABL1 p190 & p210 RT-PCR                         | N/A           | EW, BM   | Conventional<br>RT-PCR              | On arrival        | Acute Lymphoblastic<br>Leukemia<br>Chronic Myeloid<br>Leukemia                   | 2-4 working days  |                            |
| BCR::ABL1 p210 RT-<br>PCR - t(9;22)                  | N/A           | EW, BM   | Conventional<br>RT-PCR              | On arrival        | Acute Lymphoblastic<br>Leukemia<br>Chronic Myeloid<br>Leukemia                   | 2-4 working days  |                            |
| BCR::ABL1 Multiplex<br>RT-PCR (atypical<br>variants) | N/A           | EW, BM   | Conventional<br>RT-PCR              | On arrival        | Acute Lymphoblastic<br>Leukemia<br>Chronic Myeloid<br>Leukemia                   | 3-5 working days  |                            |

#### Molecular Haematopathology (ext. 8779)

| Test Name   | Ref.<br>Range | Specimen | Method                              | Test<br>Frequency                    | Panel  | Pledge TAT                         | Remarks |
|---|---------------|----------|-------------------------------------|--------------------------------------|--|------------------------------------|---------|
| BCR::ABL1 p190<br>quantitative RT-PCR                     | N/A           | EW, BM   | Real-time<br>quantitative<br>RT-PCR | once a<br>week                       | Acute Lymphoblastic<br>Leukemia                                | 7 working days                     |         |
| BCR::ABL1 p210<br>quantitative RT-PCR                     | N/A           | EW, BM   | Real-time<br>quantitative<br>RT-PCR | once a<br>week                       | Chronic Myeloid<br>Leukemia                                    | 7 working days                     |         |
| BCR::ABL1 p190/<br>p210 Kinase<br>Domain Mutation         | N/A           | EW, BM   | PCR + Sanger<br>sequencing          | On arrival                           | Acute Lymphoblastic<br>Leukemia<br>Chronic Myeloid<br>Leukemia | 3-5 working days                   |         |
| PML::RARA L and<br>S-isoform RT-PCR                       | N/A           | EW, BM   | Conventional RT-PCR                 | On arrival                           | Acute Myeloid Leukemia   | 2-4 working days                   |         |
| PML::RARA L-isoform<br>bcr1 / bcr2<br>quantitative RT-PCR | N/A           | EW, BM   | Real-time<br>quantitative<br>RT-PCR | once a<br>week                       | Acute Myeloid Leukemia   | 7 working days                     |         |
| PML::RARA S-isoform<br>bcr3 quantitative<br>RT-PCR        | N/A           | EW, BM   | Real-time<br>quantitative<br>RT-PCR | once a<br>week                       | Acute Myeloid Leukemia   | 7 working days                     |         |
| CLL FISH Panel  | N/A           | EW, BM   | FISH                                | 2 times a<br>week                    | Chronic Lymphocytic<br>Leukemia / Lymphoma                     | 5-7 working days                   |         |
| TP53 Mutation<br>(Full gene)                              | N/A           | EW, BM   | NGS                                 | once a<br>week                       | Chronic Lymphocytic<br>Leukemia / Lymphoma                     | 1 month                            |         |
| CLL FISH + TP53<br>Mutation (Combo)                       | N/A           | EW, BM   | FISH / NGS                          | 2 times<br>a week/<br>once a<br>week | Chronic Lymphocytic<br>Leukemia / Lymphoma                     | 5-7 working<br>days and<br>1 month |         |
| IGHV Somatic<br>Hypermutation<br>*(blood)                 | N/A           | EW, BM   | NGS                                 | once a<br>week                       | Chronic Lymphocytic<br>Leukemia / Lymphoma                     | 1 month                            |         |

#### Molecular Haematopathology (ext. 8779)

| Test Name   | Ref.  | Specimen                     | Method  | Test              | Panel  | Pledge TAT          | Remarks  |
|---|-------|------------------------------|---|-------------------|--|---------------------|--|
|   | Range |                              |   | Frequency         |  |                     |  |
| TCR gene rearrangement (T-cell clonality) *(blood)    | N/A   | EW, BM                       | NGS   | once a<br>week    | Chronic Lymphocytic<br>Leukemia / Lymphoma             | 1 month             |  |
| IGH / IGK detection<br>(B-cell clonality)<br>*(blood) | N/A   | EW, BM                       | NGS   | once a<br>week    | Chronic Lymphocytic<br>Leukemia / Lymphoma             | 1 month             |  |
| IG and TCR<br>detection(B+T cell<br>clonality)- Blood | N/A   | EW, BM                       | NGS   | once a<br>week    | Chronic Lymphocytic<br>Leukemia / Lymphoma             | 1 month             |  |
| IG and TCR<br>detection(B+T cell<br>clonality)- FFPE  | N/A   | FFPE                         | NGS   | once a<br>week    | Chronic Lymphocytic<br>Leukemia / Lymphoma             | 1 month             |  |
| MM FISH Panel   | N/A   | BM                           | FISH  | 2 times a week    | Multiple Myeloma                                       | 7-10 working days   |  |
| IGH::CCDN1<br>t(11;14) FISH                           | N/A   | EW, BM                       | FISH  | 2 times a<br>week | Multiple Myeloma /<br>Lymphoma                         | 7 working days      |  |
| Eosinophilia Panel                                    | N/A   | EW, BM +<br>Clotted<br>blood | FISH /<br>Conventional<br>RT-PCR / PCR<br>+ Sanger<br>Sequencing /<br>NGS | On arrival        | Myeloid and Lymphoid<br>Neoplasms with<br>eosinophilia | 5-7 working<br>days | 1 month for<br>TCR gene<br>rearrangement<br>Tryptase<br>(refer to Clinical<br>Chemistry) |

#### Molecular Haematopathology (ext. 8779)

| Test Name  | Ref.<br>Range | Specimen | Method  | Test<br>Frequency | Panel                                    | Pledge TAT          | Remarks |
|--|---------------|----------|---|-------------------|--|---------------------|---------|
| MPD Panel –<br>BCR::ABL1 p190 &<br>p210 RT-PCR, JAK2<br>exon 14 V617F, CALR<br>exon 9                  | N/A           | EW, BM   | Conventional<br>RT-PCR / Allele-<br>specific PCR<br>+ PCR-RFLP /<br>PCR-Fragment<br>Analysis/<br>PCR + Sanger<br>Sequencing | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 3-5 working<br>days |         |
| Ph-MPD Panel –<br>JAK2 exon 14 V617F,<br>CALR exon 9, MPL<br>exon 10 S505 and<br>W515 (reflex testing) | N/A           | EW, BM   | RT-PCR and<br>Sequencing  | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 7 working days      |         |
| JAK2 exon 14 V617F<br>Mutation   | N/A           | EW, BM   | Allele-specific<br>PCR + PCR-RFLP   | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 2-4 working days    |         |
| JAK2 exon 12<br>Mutation   | N/A           | EW, BM   | PCR + Sanger<br>Sequencing  | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 2-4 working days    |         |
| CALR exon 9<br>Mutation  | N/A           | EW, BM   | PCR-Fragment<br>Analysis<br>(Sanger<br>Sequencing if<br>necessary)  | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 2-4 working<br>days |         |
| MPL exon 10 \$505<br>and W515 Mutation   | N/A           | EW, BM   | PCR + Sanger<br>Sequencing  | On arrival        | Myeloproliferative<br>Neoplasm/Disorders | 2-4 working days    |         |
| MDS FISH Panel   | N/A           | EW, BM   | FISH  | 2 times a<br>week | Myelodysplastic<br>Syndrome              | 5-7 working days    |         |
| MYD88 exon 5 L265P<br>Mutation   | N/A           | EW, BM   | Allele-specific<br>PCR  | On arrival        | Haematological<br>neoplasm               | 2-4 working days    |         |

#### Molecular Haematopathology (ext. 8779)

| Test Name                            | Ref.<br>Range | Specimen            | Method                     | Test<br>Frequency | Panel                      | Pledge TAT       | Remarks                                |
|--------------------------------------|---------------|---------------------|----------------------------|-------------------|----------------------------|------------------|--|
| CXCR4 Mutation                       | N/A           | EW, BM              | PCR + Sanger<br>Sequencing | On arrival        | Haematological<br>neoplasm | 3-5 working days |  |
| CSF3R exon 14 and 17 Mutation        | N/A           | EW, BM              | PCR + Sanger<br>Sequencing | On arrival        | Haematological<br>neoplasm | 3-5 working days |  |
| STAT3 & STAT5b<br>Mutation           | N/A           | EW, BM              | PCR + Sanger<br>Sequencing | On arrival        | Haematological neoplasm    | 3-5 working days |  |
| BRAF Mutation<br>(exon 15 hotspots)  | N/A           | EW, BM              | PCR + Sanger<br>Sequencing | On arrival        | Haematological neoplasm    | 3-5 working days |  |
| PCM1::JAK2 RT-PCR                    | N/A           | EW, BM              | Conventional<br>RT-PCR     | On arrival        | Haematological neoplasm    | 7 working days   |  |
| Factor II (G20210A)<br>Mutation      | N/A           | EW                  | Real-time PCR              | On arrival        | Thrombophilia              | 1-2 working days |  |
| Factor V Leiden<br>(G1691A) Mutation | N/A           | EW                  | Real-time PCR              | On arrival        | Thrombophilia              | 1-2 working days |  |
| Factor II & V Leiden<br>Mutations    | N/A           | EW                  | Real-time PCR              | On arrival        | Thrombophilia              | 1-2 working days |  |
| MONO Blood FISH<br>(1 probe)         | N/A           | EW, Marrow<br>blood | FISH                       | 2 times a<br>week | Haematological<br>neoplasm | 3-7 working days | Probe list stated on our request form. |
| DUO Blood FISH<br>(2 probes)         | N/A           | EW, Marrow<br>blood | FISH                       | 2 times a<br>week | Haematological<br>neoplasm | 3-7 working days | Probe list stated on our request form. |
| TRIO Blood FISH (3 probes)           | N/A           | EW, Marrow<br>blood | FISH                       | 2 times a<br>week | Haematological<br>neoplasm | 3-7 working days | Probe list stated on our request form. |
| FFPE Blood Panel<br>(4 probes)       | N/A           | EW, Marrow<br>blood | FISH                       | 2 times a<br>week | Haematological<br>neoplasm | 3-7 working days | Probe list stated on our request form. |

|  |               |                 |  |                   | 1010        | iecului Olicoi      | ogy (ext. 6779)                                      |
|--|---------------|-----------------|--|-------------------|-------------|---------------------|--|
| Test Name                                  | Ref.<br>Range | Specimen        | Method                                 | Test<br>Frequency | Panel       | Pledge TAT          | Remarks  |
| Lung Cancer<br>Panel (LCMAP)               | N/A           | Tumor<br>tissue | Real-time PCR<br>+ IHC                 | 2 times a<br>week | Lung Cancer | 3-5 working days    | IHC is<br>performed by<br>Histopathology<br>Division |
| Lung Cancer<br>Panel-NGS<br>(LCMAP-NGS)    | N/A           | Tumor<br>tissue | NGS + FISH                             | once a week       | Lung Cancer | 1 month             |  |
| Lung Cancer-<br>Combo<br>(LCMAP-Combo)     | N/A           | Tumor<br>tissue | Real-time PCR<br>+ NGS + FISH<br>+ IHC | once a week       | Lung Cancer | 1 month             | IHC is<br>performed by<br>Histopathology<br>Division |
| EGFR Mutation<br>(exons 18-21<br>hotspots) | N/A           | Tumor<br>tissue | Real-time PCR                          | 2 times a<br>week | Solid Tumor | 3-5 working days    |  |
| KRAS Mutation<br>(exons 2-4<br>hotspots)   | N/A           | Tumor<br>tissue | Real-time PCR                          | 2 times a<br>week | Solid Tumor | 3-5 working days    |  |
| ALK Kinase<br>Domain Mutation              | N/A           | Tumor<br>tissue | PCR + Sanger<br>Sequencing             | On arrival        | Solid Tumor | 5-7 working days    |  |
| PIK3CA Mutation<br>(exons 9 & 20)          | N/A           | Tumor<br>tissue | PCR + Sanger<br>Sequencing             | On arrival        | Solid Tumor | 3-5 working days    |  |
| HER2 Mutation<br>(exon 20)                 | N/A           | Tumor<br>tissue | PCR + Sanger<br>Sequencing             | On arrival        | Solid Tumor | 3-5 working days    |  |
| BRAF Mutation<br>(exon 15)                 | N/A           | Tumor<br>tissue | Real-time PCR                          | On arrival        | Solid Tumor | 3-5 working days    |  |
| MET exon 14<br>skipping                    | N/A           | Tumor<br>tissue | PCR + Sanger<br>Sequencing             | On arrival        | Solid Tumor | 3-5 working<br>days |  |

| Test Name   | Ref.  | Specimen                                    | Method           | Test                             | Panel       | Pledge TAT          | Remarks |
|---|-------|---|------------------|----------------------------------|-------------|---------------------|---------|
|   | Range |   |                  | Frequency                        |             |                     |         |
| NGS-BREAST<br>PANEL - 9 genes<br>(Blood)  | N/A   | EW,<br>Clotted<br>blood                     | NGS              | once a week                      | Solid Tumor | 1 month             |         |
| Somatic BRCAI &<br>BRCA2 Mutation<br>by NGS   | N/A   | Tumor<br>tissue                             | NGS              | once a week                      | Solid Tumor | 1 month             |         |
| Combo BRCA<br>gene NGS Panel<br>(Blood and FFPE)  | N/A   | EW,<br>Clotted<br>blood,<br>Tumor<br>tissue | NGS              | once a week                      | Solid Tumor | 1 month             |         |
| BRCA1 or BRCA2<br>or PTEN or TP53<br>large genomic<br>rearrangement<br>detection by<br>MLPA | N/A   | EW, Tumor<br>tissue                         | MLPA             | On arrival                       | Solid Tumor | 5-7 working<br>days |         |
| BRCA1 Known<br>Mutation (Blood)   | N/A   | EW,<br>Clotted<br>blood                     | PCR & sequencing | Prior<br>arrangement<br>required | Solid Tumor | 5-7 working days    |         |
| BRCA2 Known<br>Mutation (Blood)   | N/A   | EW,<br>Clotted<br>blood                     | PCR & sequencing | Prior<br>arrangement<br>required | Solid Tumor | 5-7 working days    |         |
| Targeted<br>genes by NGS<br>(Blood/ FFPE)   | N/A   | EW,<br>Clotted<br>blood,<br>Tumor<br>tissue | NGS +/- MLPA     | once a week                      | Solid Tumor | 1 month             |         |

#### Molecular Oncology (ext. 8779)

| Test Name   | Ref.<br>Range | Specimen                                    | Method                     | Test<br>Frequency | Panel        | Pledge TAT        | Remarks  |
|---|---------------|---|----------------------------|-------------------|--------------|-------------------|--|
| Colon Cancer<br>Panel (CCMAP)   | N/A           | Tumor<br>tissue                             | Real-time PCR<br>+ IHC     | 2 times a<br>week | Solid Tumor  | 3-5 working days  | IHC is<br>performed by<br>Histopathology<br>Division |
| NRAS Mutation   | N/A           | Tumor<br>tissue                             | Real-time PCR              | 2 times a<br>week | Solid Tumor  | 3-5 working days  |  |
| Microsatellite Instability (MSI)  | N/A           | EW, Tumor<br>Tisse                          | PCR-Fragment<br>Analysis   | once a week       | Solid Tumor  | 7-10 working days |  |
| MMR genes<br>by NGS<br>(Blood/ FFPE)  | N/A           | EW,<br>Clotted<br>blood,<br>Tumor<br>tissue | NGS + MLPA                 | once a week       | Solid Tumor  | 1 month           |  |
| FAP APC &<br>MUTYH Full Gene<br>Mutation by NGS<br>(Blood/ FFPE)                | N/A           | EW,<br>Clotted<br>blood,<br>Tumor<br>tissue | NGS + MLPA                 | once a week       | Colon Cancer | 1 month           |  |
| MLH1 / MSH2 /<br>PMS2 / MSH6 /<br>APC / MUTYH<br>Known Mutation<br>(Blood/FFPE) | N/A           | EW/<br>Tumour<br>tissue                     | PCR + Sanger<br>Sequencing | once a week       | Colon Cancer | 3-5 working days  |  |

## Molecular Oncology (ext. 8779)

| Test Name   | Ref.<br>Range | Specimen                      | Method   | Test<br>Frequency | Panel        | Pledge TAT           | Remarks |
|---|---------------|-------------------------------|--|-------------------|--------------|----------------------|---------|
| MLH1 / MSH2 /<br>PMS2 / MSH6 /<br>APC / MUTYH<br>large genomic<br>rearrangement<br>detection by<br>MLPA (Blood) | N/A           | EW/<br>Tumour<br>tissue       | MLPA   | once a week       | Colon Cancer | 5-7 working<br>days  |         |
| MLH1 / MSH2 /<br>PMS2 / MSH6<br>Promoter<br>Methylation by<br>MLPA (Blood /<br>FFPE)                            | N/A           | EW/<br>Tumour<br>tissue       | MLPA   | once a week       | Colon Cancer | 5-7 working days     |         |
| Brain Cancer<br>Panel (1p/19q<br>FISH, IDH1, IDH2,<br>MGMT)   | N/A           | Noraml<br>and Tumor<br>tissue | FISH + PCR<br>+ Sanger<br>Sequencing +<br>MLPA | once a week       | Brain Cancer | 7-10 working<br>days |         |
| IDH1 & IDH2<br>Hotspots Mutation  | N/A           | Tumor<br>tissue               | PCR + Sanger<br>Sequencing                     | On arrival        | Solid Tumor  | 3-5 working days     |         |
| MGMT Promoter<br>Methylation by<br>MLPA   | N/A           | Noraml<br>and Tumor<br>tissue | MLPA   | once a week       | Solid Tumor  | 5-7 working days     |         |
| KIT Mutation  | N/A           | Tumor<br>tissue               | PCR + Sanger<br>Sequencing                     | On arrival        | Solid Tumor  | 3-5 working days     |         |
| PDGFRA Mutation   | N/A           | Tumor<br>tissue               | PCR + Sanger<br>Sequencing                     | On arrival        | Solid Tumor  | 3-5 working days     |         |
| KIT & PDGFRA<br>Mutation  | N/A           | Tumor<br>tissue               | PCR + Sanger<br>Sequencing                     | On arrival        | Solid Tumor  | 3-5 working days     |         |

#### Molecular Oncology (ext. 8779)

| Test Name   | Ref.<br>Range | Specimen          | Method   | Test<br>Frequency | Panel       | Pledge TAT                          | Remarks                                     |
|---|---------------|-------------------|--|-------------------|-------------|-------------------------------------|---|
| MONO FFPE FISH<br>(1 probe)   | N/A           | Tumor<br>tissue   | FISH   | 2 times a<br>week | Solid Tumor | 3-7 working days                    | Probe list stated<br>on our request<br>form |
| DUO FFPE FISH<br>(2 probes)   | N/A           | Tumor<br>tissue   | FISH   | 2 times a<br>week | Solid Tumor | 3-7 working days                    | Probe list stated<br>on our request<br>form |
| TRIO FFPE FISH (3 probes)   | N/A           | Tumor<br>tissue   | FISH   | 2 times a week    | Solid Tumor | 3-7 working days                    | Probe list stated<br>on our request<br>form |
| FFPE FISH Panel<br>(4 probes)   | N/A           | Tumor<br>tissue   | FISH   | 2 times a<br>week | Solid Tumor | 3-7 working days                    | Probe list stated on our request form.      |
| Other molecular test by special request (genetic test, Structural Rearrangement Breakpoint Mapping) | N/A           | EW, BM,<br>Tissue | PCR/Sanger<br>Sequencing/<br>MLPA/FISH/<br>Long-read PCR-<br>free nanopore<br>sequencing | On arrival        | N/A         | Depends<br>on the test<br>requested | Please contact<br>our divison in<br>advance |

EW = EDTA whole blood NGS = Next-generation sequencing ddPCR = Droplet digital polymerase chain reaction FFPE = Formalin-fixed, paraffin-embedded tissue

RFLP = Restriction fragment length polymorphism

BM = Bone marrow

RT-PCR = Reverse transcriptase polymerase chain reaction

FISH = Fluorescent in-situ hybridisation

MLPA = Multiplex Ligation-dependent Probe Amplification



|  | Male/        | Fermale | Ferr | nale |
|--|--------------|---------|------|------|
| Health Assessment Schemes                | Α            | В       | С    | D    |
| Medical History                          | $\checkmark$ | ✓       | ✓    | ✓    |
| Complete Physical Examiniation           | ✓            | ✓       | ✓    | ✓    |
| Laboratory Investigation                 |              |         |      |      |
| Complete Blood Count including Platelet  | ✓            | ✓       | ✓    | ✓    |
| Blood Film                               | ✓            | ✓       | ✓    | ✓    |
| E.S.R.                                   | ✓            | ✓       | ✓    | ✓    |
| *Blood Grouping and Rh Typing            | ✓            | ✓       | ✓    | ✓    |
| *G6PD                                    | ✓            | -       | ✓    | -    |
| Kidney Function: Urea                    | ✓            | ✓       | ✓    | ✓    |
| Creatinine                               | ✓            | ✓       | ✓    | ✓    |
| Electrolytes: Na, K                      | ✓            | ✓       | ✓    | ✓    |
| Calcium                                  | ✓            | ✓       | ✓    | ✓    |
| Liver Function: Albumin adjusted calcium | ✓            | ✓       | ✓    | ✓    |
| Bilirubin, total and direct              | ✓            | ✓       | ✓    | ✓    |
| A. S. T.                                 | ✓            | ✓       | ✓    | ✓    |
| A. L.T.                                  | ✓            | ✓       | ✓    | ✓    |
| Alkaline phosphatase                     | ✓            | ✓       | ✓    | ✓    |
| Gamma GT                                 | ✓            | ✓       | ✓    | ✓    |





| Charge Code | Details                                      | Tests   |
|-------------|--|---|
| 465-4       | Ante-Natal Screening Package                 | CBP, Blood group & Rh(D), Treponema pallidum Ab, Rubella Ab-IgG,<br>HBsAg, HIV 1 + 2 Ab/p24 Ag  |
| 418-2       | Arthritis Panel                              | CBP, ESR, uric acid, albumin, globulin, CRP, RA factor screen, ANA, Anti-CCP IgG  |
| 408-5       | Cardiology check-up package                  | CBP, urea, creatinine, sodium, potassium, glucose fasting, ALT, Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, hs-CRP          |
| 409-3       | Cardiology 1st line intervention             | Total cholesterol, HDL cholesterol, LDL cholesterol, Triglycerides, hs-CRP  |
| 410-7       | Cardiology 2 <sup>nd</sup> line intervention | Homocysteine, Apo A-1, Apo B, Lp(a), urine microalbumin   |
| 90037-4     | Child Health Program (plan y – 9 month)      | CBP, urine routine, HBsAb screening   |
| 90038-2     | Child Health Program (plan z - 6 years)      | CBP, urine routine, urea, creatinine, total cholesterol, ALT  |
| 504-9       | Female Hormone Profile 1                     | E2, LH, FSH   |
| 505-7       | Female Hormone Profile 2                     | E2, LH, FSH, Prolactin  |
| 506-5       | Female Hormone Profile 3                     | E2, LH  |
| 507-3       | Female Hormone Profile 4                     | DHEA-S, E2, FSH, LH, Prolactin  |
| 470-1       | Lipid Profile                                | Cholesterol(total), HDL, LDL, Triglyceride, cholesterol/HDL Ratio, Non-HDL cholesterol  |
| 468-9       | Liver Function Test (LFT 2)                  | Total & direct bilirubin, ALP, AST, ALT, GGT, Total Protein, Albumin, Globulin  |
| 467-1       | Pre-Marriage Checkup (Female)                | CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HBA1c, Chickenpox IgG, Urine routine |
| 466-2       | Pre-Marriage Checkup (Male)                  | CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HBA1c, Urine routine, Semen Analysis                 |
| 503-1       | Pre-pregnancy Profile                        | CBP, Blood Group & Rh(D), Treponema pallidum Ab for Syphilis, Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, Chickenpox IgG                       |

| Charge Code | Details  | Tests  |
|-------------|--|--|
| 469-7       | Renal Function Test (RFT 2)                              | Urea, creatinine, sodium, potassium, chloride, bicarbonate   |
| 432-8       | Thrombosis panel   | Antithrombin, Protein C, Protein S, APCR, Lupus anticoagulant,<br>Anti-cardiolipin Ab  |
| 90046-3     | Genital Infection Package A                              | Culture & Sensitivity (including G.C.), Trichomonas & Monilia, Gonococcal & Chlamydia trachomatis-DNA and Mycoplasma hominis/ Ureaplasma urealyticum C&ST (Gel swab for culture, non-gel swab for Mycoplasma, Amplicor STD swab for DNA) |
| 90047-1     | Genital Infection Package B                              | Treponema Pallidum Ab for Syphilis, HIV 1 + 2 Ab/p24 Ag  |
| 90058-7     | Genital Infection Package C                              | Culture & Sensitivity (including G.C.), Trichomonas & Monilia, Gonococcal & Chlamydia trachomatis-DNA (Gel swab for culture specimen and Amplicor STD Swab for DNA)  |
| 542-1       | STD screening (1st visit) (Female)                       | CBP, Blood Group & Rh(D), Rubella Ab-IgG, HBsAg, HBsAb, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL  |
| 541-3       | STD screening (1st visit) (Male)                         | CBP, HBsAg, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL  |
| 543-0       | STD screening (2 <sup>nd</sup> visit)<br>(Female / Male) | HBsAg, HIV 1+2 Ab/p24 Ag, HCV Ab, VDRL   |
| 540-5       | Well Women Screening Program                             | CBP, Urine routine   |
| 832-3       | Pre-operation coagulation screen                         | CBP, PT, APTT, PFA-100   |
| 833-1       | Comprehensive screen for bleeding disorder               | CBP, PT, APTT, Fibrinogen, TT, D-Dimer   |
| 834-0       | VWD panel  | CBP, PT, APTT, PFA-100, VWF Ag, VWF Ac, Factor VIII  |
| 835-8       | Haemophilia panel  | CBP, PT, APTT, PFA-100, Factor VIII, Factor IX   |



# GUIDELINES / PATIENT NOTES FOR SPECIAL TESTS

#### **Guidelines / Patient Notes for Special Tests**

The general and brief information listed below is for the use by medical personnel when providing instructions to patients on the following special tests. For further details of these tests, please contact the Clinical Laboratory at 2835-8790.

#### <sup>13</sup>c Urea Breath Test

Fasting must be observed for at least 4 hours prior to testing. In addition, some medications, such as antibiotics, proton-pump inhibitors, etc. may affect test accuracy and should be stopped beforehand. For a comprehensive list of medications, please contact the Clinical Laboratory.

#### 24 HOUR URINE

Patients are requested to visit our Clinical Laboratory and obtain a special specimen container for urine collection. Please advise patients not to touch / pour away the chemicals inside the container. The container should be kept in a cool, dry place for the duration of sample collection. Patients should void and discard a urine sample before commencing collection. Thereafter, all urine voided in the next 24 hours must be collected completely in the container. For creatinine clearance, the patient's height and weight must be obtained with a blood sample within 48 hours before or after urine collection. Sampling during menstruation should be avoided.

#### Interpretation Chart for EBV Ab-IgM & IgG for Infectious Mononucleosis

|                  | lgM      | IgG | lgM                          | IgG | lgM                               | lgG                      | IgM | IgG |
|------------------|----------|-----|------------------------------|-----|-----------------------------------|--------------------------|-----|-----|
| Anti-<br>EBNA-1  | -        | -   | +/-                          | -   | -                                 | -/+                      | -   | -/+ |
| Anti-p22         | -        | -   | +/-                          | -   | -                                 | +                        | -   | +   |
| Anti-VCA         | -        | -   | +                            | -/+ | -                                 | +                        | +   | +   |
| Anti-EA D        | -        | -   | +                            | +/- | -                                 | -                        | +   | +   |
| Infection status | Negative |     | Primary /<br>Acute Infection |     | Convalescence /<br>Past Infection | Reactivated<br>Infection |     |     |

#### **Fasting Sample Definition**

While there are various different guidelines on the definition of fasting, the Hospital has established a general guideline using information from the American Diabetes Association: a fasting period is defined as "no calorie intake for at least 8 hours". It is recommended that patients do not eat after midnight at the latest, and proceed to the Laboratory for blood tests in the morning. They may have small sips of water while fasting.

## **Semen Analysis**

Semen analysis is done by automated analyzer. Patients are required to abstain from sexual activity 3-5 days prior to sample collection. A suitable container will be provided by the Clinical Laboratory. Semen samples should be obtained by masturbation and collected directly into a container without using condoms. The collection time should be recorded. The sample should reach the Clinical Laboratory within an hour after collection, ideally kept warm to simulate body conditions.



**APPENDIX** 

| Analytes               | Unit   | Phone Value        |                   | Critical Value |       | Department of He | ealth Assessment |
|------------------------|--------|--------------------|-------------------|----------------|-------|------------------|------------------|
| ,                      |        |                    |                   |                |       | Phone Value      |                  |
| Blood gases pH         |        | <7.3               |                   |                |       |                  |                  |
| Glucose, fasting       | mmol/L | <3.0               | >8.0              | <2.0           | >28.0 | <3.0             | >8.0             |
| Glucose, random        | mmol/L | <3.0               | >12.0             | <2.0           | >28.0 | <3.0             | >12.0            |
| Sodium                 | mmol/L | <125               | >155              | <120           | >165  | <125             | >150             |
| Potassium              | mmol/L | <3.0               | >5.4              | <2.5           | >7.0  | <3.0             | >5.4             |
| Chloride               | mmol/L | <75                | >125              |                |       |                  |                  |
| Urea                   | mmol/L |                    | >33.4             |                |       |                  | >15.0            |
| Creatinine             | umol/L |                    | >618              |                |       |                  | >200             |
| Calcium,               | mmol/L | <1.90              | >2.80             | <1.75          | >3.25 | <1.90            | >3.00            |
| albumin                |        |                    |                   |                |       |                  |                  |
| adjusted               |        |                    |                   |                |       |                  |                  |
| Ionized Calcium        | mmol/L | <1.12              | >1.35             | <0.78          | >1.58 |                  |                  |
| Amylase, total         | U/L    |                    | >400              |                | >1000 |                  | >400             |
| Amylase,<br>pancreatic | U/L    |                    | >400              |                |       |                  | >400             |
| Total bilirubin        | umol/L |                    | >239              |                |       |                  | >239             |
| AST                    | U/L    |                    | >200              |                |       |                  | >200             |
| ALT                    | U/L    |                    | >400              |                |       |                  | >400             |
| Total protein          | g/L    | <50                | >100              |                |       | <50              | >100             |
| Albumin                | g/L    | <20                |                   |                |       | <20              |                  |
| CK                     | U/L    |                    | >500              |                | >1000 |                  | >500             |
| LDH                    | U/L    |                    | >400              |                |       |                  | >400             |
| Magnesium              | mmol/L | <0.6               |                   | < 0.4          |       | <0.6             |                  |
| Phosphorus             | mmol/L | <0.48              | >2.81             |                |       | <0.48            | >2.81            |
| Triglycerides          | mmol/L |                    |                   |                | >30.0 |                  | >10.0            |
| Neonatal               | umol/L | All outpatient res | ults if requested |                | >340  |                  |                  |
| bilirubin              |        |                    |                   |                |       |                  |                  |

#### Hematology

| Analytes                | Unit   | Phone Value |          | Critical Value    |                   | Department of He<br>Phone Value | ealth Assessment |
|-------------------------|--------|-------------|----------|-------------------|-------------------|---------------------------------|------------------|
| Haemoglobin *           | g/dL   | <8.0        | >19.0    | <6.5              | >20.0             | <10.0                           | >19.0            |
| WBC *                   | 109 /L | <1.0        | >50.0    | <0.5              | >80.0             | <2.5                            | >13.0            |
| Platelet *              | 109 /L | <50         | >600     | <10               | >1000             | <100                            | >600             |
| Malaria parasites       |        |             | Positive |                   |                   |                                 |                  |
| Blood film              |        |             | I        | Leukemia or other | r blood dyscrasia | S                               |                  |
| Prothrombin time (PT) ^ | sec    |             | >40      |                   | >60               |                                 |                  |
|                         | INR    |             | >4.0     |                   | >4.5              |                                 |                  |
| APTT ^                  | sec    |             | >60      |                   | >120              |                                 |                  |

<sup>\*</sup> Unless the patient is having similar values on delta check (eg. Oncology patient) or previous result is being phoned already.

The above figures are for internal reference only and subject to regular updates.

The above figures are for internal reference only and subject to regular updates.

<sup>^</sup> Unless the patient is having similar values on delta check or is known to be on warfarin therapy.

#### COMMONLY USED LABORATORY FORMULAE

#### 1. Creatinine Clearance

The creatinine clearance is calculated based on serum and timed urine collection for creatinine measurement. It is an assessment of glomerular filtration rate and hence renal function. The creatinine clearance is more sensitive than serum creatinine in the detection of early glomerular dysfunction. Please note that significant decrease in creatinine clearance may not occur until up to 30% of glomeruli cease to function. Complete and accurately timed urine collection is essential. The height and weight of the patient should be measured for the surface area to be calculated and the creatinine clearance adjusted to the standard body surface area of 1.73m<sup>2</sup>.

Creatinine Clearance (ml/min/1.73m<sup>2</sup>) = [Urine creatinine (mmol/L) x Urine volume (mL) x 1.73]  $\div$  [Plasma creatinine (mmol/L) x Time (min) x Body surface area (m<sup>2</sup>)]

#### 2. Friedewald Equation

LDL cholesterol (mmol/L) = Total cholesterol (mmol/L) - HDL cholesterol (mmol/L) - [Triglyceride (mmol/L)  $\times$  0.46]

LDL cholesterol result is directly measured rather than calculated from Friedewald Equation unless otherwise specified.

## 3. Estimated Glomerular Filtration Rate (eGFR)

The modified MDRD formula for Chinese patients is adopted for better correlation with creatinine clearance measurement in the Chinese population. Please note that the modified formula gives a slightly higher eGFR result than the original MDRD formula, especially in females and at high GFR values. The eGFR may not be accurate in people at extremes of body type, e.g. the malnourished and the amputees. Its validity has not been tested across all ethnic groups. The eGFR is not valid in pregnant women and children.

Chronic renal disease is unlikely when the eGFR is >60 ml/min/1.73m<sup>2</sup> and in the absence of clinical evidence of kidney disorder. Moreover, in persons  $\geq$  70 years of age, an eGFR value in the range of 45 – 59 ml/min/1.73m<sup>2</sup>, if stable over time and unaccompanied by evidence of renal damage, may be interpreted as typical for this age group and unlikely to be associated with chronic renal disease.

MDRD (Modification of Diet in Renal Disease) formula traceable to IDMS:

eGFR (ml/min/1.73m<sup>2</sup>) = 175 x [serum creatinine ( $\mu$ mol/L)÷88.4]<sup>-1.154</sup> x Age<sup>-0.203</sup> x 0.742 (if female)

Modified MDRD formula for Chinese (J Am Soc Nephrol 17: 2937 - 44, 2006):

eGFR (ml/min/1.73m<sup>2</sup>) = 175 x [serum creatinine ( $\mu$ mol/L)÷88.4]<sup>-1.234</sup> x Age<sup>-0.179</sup> x 0.79 (if female)

## 4. HbA1c-estimated Average Glucose (eAG)

eAG (mmol/L) =  $[28.7 \text{ x HbA1c} (\%) - 46.7] \div 18 \text{ or}$ 

eAG (mmol/L) =  $[2870 \times HbA1c \text{ (fraction)} - 46.7] \div 18$ 

The estimated Average Glucose (eAG) is a new parameter recommended by the American Diabetes Association in 2008 and replaces the mean plasma glucose. The eAG equation is based on the A1c-derived Average Glucose (ADAG) Study published in Diabetes Care 31: 1473 – 8, 2008, which has confirmed the existence of a linear relationship between HbA1c and average blood glucose level. The eAG value is slightly lower than the previously used mean plasma glucose value.

## 5. Albumin Adjusted Calcium (AACA)

Free calcium, the physiological active form can be estimated using mathematical calculation of total calcium and albumin level.

AACA (mmol/L) = plasma calcium (mmol/L) + 0.012 [40.3 - plasma albumin (g/L)]

#### CLINICAL CHEMISTRY UNIT CONVERSION TABLE


| Test Name            | SI Unit     | Conventional Unit | Convers            | ion Factor         |
|----------------------|-------------|-------------------|--------------------|--------------------|
|                      |             |                   | SI to Conventional | Conventional to SI |
| Acetaminophen        | µmol/L      | μg/mL             | 0.1512             | 6.614              |
| Albumin              | g/L         | g/dL              | 0.1                | 10                 |
| Amikacin             | µmol/L      | μg/mL             | 0.5848             | 1.71               |
| Ammonia              | µmol/L      | μg/dL             | 1.70               | 0.5872             |
| Bilirubin            | µmol/L      | mg/dL             | 0.058              | 17.1               |
| Calcium              | mmol/L      | mg/dL             | 4                  | 0.25               |
| Carbamazepine        | µmol/L      | μg/mL             | 0.2364             | 4.23               |
| Cholesterol, Total   | mmol/L      | mg/dL             | 38.7               | 0.02586            |
| Cortisol             | nmol/L      | μg/dL             | 0.0362             | 27.6               |
| Creatinine           | µmol/L      | mg/dL             | 0.0113             | 88.4               |
| Creatinine Clearance | ml/sec/sq.m | ml/min/1.73sq.m   | 103.8              | 0.0096             |
| Cyclosporine A       | nmol/L      | ng/mL             | 1.205              | 0.83               |
| Digoxin              | nmol/L      | ng/mL             | 0.7813             | 1.28               |
| Estradiol            | pmol/L      | pg/mL             | 0.2725             | 3.67               |
| Folate               | nmol/L      | ng/mL             | 0.4415             | 2.265              |
| Free T3              | pmol/L      | pg/dL             | 65                 | 0.0154             |
| Free T4              | pmol/L      | ng/dL             | 0.0777             | 12.87              |
| FSH                  | IU/L        | mlU/mL            | 1                  | 1                  |
| Gentamicin           | µmol/L      | μg/mL             | 0.4785             | 2.09               |
| Glucose              | mmol/L      | mg/dL             | 18.0               | 0.0555             |
| HDL-cholesterol      | mmol/L      | mg/dL             | 38.7               | 0.02586            |
| Homocysteine         | µmol/L      | μg/mL             | 0.1352             | 7.396              |
| Inorganic Phosphorus | mmol/L      | mg/dL             | 3.097              | 0.3229             |
| Insulin              | pmol/L      | μlU/mL            | 0.1394             | 7.175              |
| Iron                 | µmol/L      | µg/dL             | 5.58               | 0.1791             |
| LDL-Cholesterol      | mmol/L      | mg/dL             | 38.7               | 0.02586            |
| LH                   | IU/L        | mIU/mL            | 1                  | 1                  |
| Magnesium            | mmol/L      | mg/dL             | 2.43               | 0.4114             |

| Test Name              | SI Unit          | Conventional Unit | Conv               | version Factor     |
|------------------------|------------------|-------------------|--------------------|--------------------|
|                        |                  |                   | SI to Conventional | Conventional to SI |
| Microalbumin to        | mg albumin/ mmol | mg albumin/ g     | 8.85               | 0.113              |
| creatinine ratio       | creatinine       | creatinine        |                    |                    |
| Netilmicin             | µmol/L           | μg/mL             | 0.4762             | 2.10               |
| NT-proBNP              | pmol/L           | pg/ml             | 8.457              | 0.118              |
| Osmolality             | mmol/kg          | mOsmol/kg         | 1                  | 1                  |
| Phenobarbital          | µmol/L           | μg/mL             | 0.232              | 4.31               |
| Phenytoin (Dilantin)   | µmol/L           | μg/mL             | 0.2525             | 3.96               |
| Progesterone           | nmol/L           | ng/mL             | 0.3145             | 3.18               |
| Prolactin              | mIU/L            | ng/ml             | 0.0472             | 21.2               |
| Protein                | g/L              | g/dL              | 0.1                | 10                 |
| PTH                    | pmol/L           | ng/mL             | 0.01               | 100                |
| RBC-G6PD               | MU/mol Hb        | U/g Hb            | 15.5               | 0.0645             |
| Quantitative Test      |                  |                   |                    |                    |
| Salicylate (Aspirin)   | mmol/L           | mg/dL             | 13.812             | 0.0724             |
| T3                     | nmol/L           | ng/dL             | 65                 | 0.0154             |
| T4                     | nmol/L           | μg/dL             | 0.0777             | 12.87              |
| Testosterone           | nmol/L           | ng/dL             | 28.8               | 0.0347             |
| Theophylline           | µmol/L           | μg/mL             | 0.1802             | 5.55               |
| TIBC                   | μmol/L           | μg/dL             | 5.5835             | 0.179              |
| Tobramycin (Nebcin)    | μmol/L           | μg/mL             | 0.4673             | 2.14               |
| Triglycerides          | mmol/L           | mg/dL             | 88.57              | 0.01129            |
| TSH                    | mIU/L            | µIU/mL            | 1                  | 1                  |
| Urea                   | mmol/L           | mg/dL             | 5.988              | 0.167              |
| Uric acid              | mmol/L           | mg/dL             | 16.95              | 0.059              |
| Valproic Acid (Epilim) | µmol/L           | μg/mL             | 0.1443             | 6.93               |
| Vancomycin             | µmol/L           | μg/mL             | 1.4493             | 0.69               |
| Vitamin B12            | pmol/L           | pg/mL             | 1.355              | 0.738              |
| β-hCG                  | IU/L             | mIU/mL            | 1                  | 1                  |

# NT-probnp in Heart failure


## Clinical Use of NT-proBNP in the Diagnosis of Heart Failure

Acute setting



## Clinical Use of NT-proBNP in the Diagnosis of Heart Failure

Non-Acute Setting







# **INDEX**

| 24 hr Urinary calcium                        | 40    |
|--|-------|
| 24 hr Urinary creatinine                     | 40    |
| 24 hr Urinary inorganic phosphorus           | 40    |
| 24 hr Urinary potassium                      | 40    |
| 24 hr Urinary protein                        | 40    |
| 24 hr Urinary sodium                         | 40    |
| 24 hr Urinary urea                           | 40    |
| Ab-lgG                                       | 52    |
| Ab-lgG/lgM                                   | 52    |
| Acetaminophen                                | 95    |
| Activated partial thromboplastin time        | 42    |
| Activated Protein C Resistance (APCR) ratio  | 43    |
| ADAMTS 13 Antigen & Auto-Antibody            | 49    |
| ADAMTS Activity                              | 49    |
| Adrenocorticotropic hormone (ACTH)           | 19    |
| AFB Stain                                    | 46    |
| Agglutinin                                   | 17    |
| Alanine aminotransferrase (ALT)              | 19    |
| Albumin                                      | 19,95 |
| ALK Kinase Domain Mutation                   | 76    |
| Alkaline phosphatase (ALP)                   | 19    |
| Allergen component IgE                       | 19    |
| Allergen speciic Immunoglobulin IgG and IgG4 | 29    |
| Alpha-fetoprotein (AFP)                      | 19    |
| Amikacin                                     | 19,95 |
| Ammonia                                      | 19,95 |
| Amoeba                                       | 46    |
| Amylase                                      | 19    |
| Amylase (drain fluid)                        | 20    |
| Amylase, pancreatic                          | 20    |
|  |       |

| Anaerobic Culture  | 46 |
|--|----|
| ANCA   | 49 |
| ANCA-MPO &   | 49 |
| ANCA-PR3   | 49 |
| Anti-Cardiolipin   | 49 |
| Anti-CCP (cyclic citrullinated peptide)  | 49 |
| Anti-ds DNA  | 49 |
| Anti-ENA Profile by ELISA (Ribosomal P proteins, nRNP/<br>Sm, Sm, SS-A, SS-B, ScI-70, Jo-1 & Centromeres)  | 50 |
| Anti-ENA Profile by Immunoblot (Mi-2, Ku, nRNP/Sm,<br>Sm, SS-A,Ro-52, SS-B, ScI-70, PM-ScI, Jo-1, CENP-B, PCNA,<br>dsDNA, Nucleosomes, Histones, Rib P protein, AMA, M2,<br>DFS70) | 50 |
| Anti-Nuclear Antibody (ANA)  | 50 |
| Anti-PF4 IgG   | 50 |
| Anti-PM-Scl IgG  | 50 |
| Anti-thyroglobulin   | 20 |
| Anti- 2 Glycoprotein 1 IgG & IgM   | 51 |
| Antibody Test  | 55 |
| Antithrombin   | 43 |
| Apixaban (Eliquis monitoring)  | 44 |
| Apolipoprotein A1  | 20 |
| Apolipoprotein B   | 20 |
| Ascitic fluid - Glucose  | 20 |
| Ascitic fluid - Protein  | 20 |
| Ascitic fluid routine analysis (pH, WBC, D/C, RBC, Glucose, Protein)   | 58 |
| Ascitic fluid- LDH   | 20 |
| Aspartate aminotransferase (AST)   | 20 |
| Aspergillus Galactaomannan Antigen   | 51 |

| Auto C-PAP  | 61 |
|---|----|
| Autoimmune Inflammatory Myopathy (Anti-Mi-2, Anti-Mi-2, Anti-TiF1, Anti-MDA5, Anti-NXP2, Anti-SAE1, Anti-Ku, Anti-PM-ScI-100, Anti-PM-ScI-75, Anti-Jo-1, Anti-SRP, Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-Ro-52, Anti-cN-1A, Anti-HMGCR) | 51 |
| Autologous serum PEG  | 61 |
| Autologous Transfusion  | 18 |
| b-human chorionic gonadotropin (hCG)  | 21 |
| Bacterial Antigen Screen (H.influenza b, Strep B,   | 52 |
| Pneumococcus, Meningococcus, E. coli)   |    |
| Basophil  | 41 |
| BCR::ABL1 Multiplex RT-PCR (atypical variants)  | 71 |
| BCR::ABL1 p190 & p210 RT-PCR  | 71 |
| BCR::ABL1 p190 quantitative RT-PCR  | 72 |
| BCR::ABL1 p190/p210 Kinase Domain Mutation  | 72 |
| BCR::ABL1 p210 quantitative RT-PCR  | 72 |
| BCR::ABL1 p210 RT-PCR - t(9;22)   | 71 |
| beta-CrossLaps (CTX)  | 20 |
| Bicarbonate (HCO3)  | 21 |
| Bilirubin   | 95 |
| Bilirubin, conjugated   | 21 |
| Bilirubin, total  | 21 |
| Biopsy (Routine)  | 62 |
| Biopsy (Urgent quick section by rapid tissue  | 66 |
| processing)   |    |
| Bleeding Time (Platelet function by PFA-100)  | 44 |
| Blood   | 17 |
| Blood Culture   | 46 |
| Blood film review by Hosp. Haematologist  | 42 |

| Blood Gas  | 21     |
|--|--------|
| Body cavity fluid for cytology                     | 65     |
| Bone Marrow Reporting by Hosp. Haematologist       | 45     |
| BRAF Mutation (exon 15 hotspots)                   | 75     |
| BRAF Mutation (exon 15)                            | 76     |
| Brain Cancer Panel (1p/19q FISH, IDH1, IDH2, MGMT) | 79     |
| BRCA1 Known Mutation (Blood)                       | 77     |
| BRCA1 or BRCA2 or PTEN or TP53 large genomic       | 77     |
| rearrangement detection by MLPA                    |        |
| BRCA2 Known Mutation (Blood)                       | 77     |
| Breast Cancer Markers (ER; PR; Ki67; Her2)         | 62     |
| Bronchial washing                                  | 65     |
| Bronchial-alveolar lavage                          | 65     |
| Brucella Agglutination Test                        | 52     |
| Brushing (bronchial, CBD, etc)                     | 65     |
| C-Reactive protein                                 | 23     |
| CA125  | 21     |
| CA15.3   | 21     |
| CA19.9   | 21     |
| CA72.4   | 22     |
| Calcium  | 22, 95 |
| Calcium, ionized                                   | 22     |
| CALR exon 9 Mutation                               | 74     |
| Carbamazepine                                      | 95     |
| Carboxyhaemoglobin                                 | 22     |
| Carcinoembryonic antigen (CEA)                     | 22     |
| CBFB::MYH11 Type A quantitative RT-PCR             | 71     |
| CBFB/MYH11 (inv 16) RT-PCR                         | 70     |
| CD34 enumeration                                   | 60     |
| CEBPA Mutation                                     | 71     |

| Cerebro-spinal fluid (CSF)                             | 65     | CSF- Glucose                                  | 22     |
|--|--------|---|--------|
| Chlamydia pneumoniae                                   | 52     | CSF- IgG                                      | 22     |
| Chlamydia trachomatis                                  | 52     | CSF- IgG Index                                | 22     |
| Chlamydia trachomatis PCR                              | 67     | CSF- Protein                                  | 22     |
| Chloride   | 22     | CSF3R exon 14 and 17 Mutation                 | 75     |
| Cholesterol, total                                     | 22, 95 | Culture & Sensitivity                         | 46     |
| Cholesterol, total to HDL-Cholesterol Ratio            | 22     | CXCR4 Mutation                                | 75     |
| CKMB   | 23     | Cyclosporin A                                 | 23     |
| CLL FISH + TP53 Mutation (Combo)                       | 72     | Cyclosporine A                                | 95     |
| CLL FISH Panel   | 72     | Cytochemistry & Reporting                     | 45     |
| Clostridium difficile Culture                          | 46     | Cytomegalovirus IgG                           | 23     |
| Clostridium difficile Toxin PCR                        | 69     | Cytomegalovirus IgM                           | 23     |
| CMV DNA Quantitative PCR                               | 67     | D-dimer (Quantitative)                        | 43     |
| Cold   | 17     | Dehydroepiandrosterone sulfate (DHEA-S)       | 24, 25 |
| Colon Cancer Panel (CCMAP)                             | 78     | Dengue Virus Ab IgG, IgM and NS1 Rapid Test   | 52     |
| Combo BRCA gene NGS Panel (Blood and FFPE)             | 77     | Digoxin                                       | 25, 95 |
| Complement C3  | 23     | Direct  | 17     |
| Complement C4  | 23     | DUO Blood FISH (2 probes)                     | 75     |
| Complete blood picture (CBP)                           | 41     | DUO FFPE FISH (2 probes)                      | 80     |
| Consultation and Review                                | 62     | E.S.R.  | 42     |
| Coombs   | 17     | EBV Ab IgM & IgG for infectious mononucleosis | 53     |
| Cortisol   | 23, 95 | EBV Ab-IgA                                    | 53     |
| CPE Screen   | 46     | EBV DNA Quantitative PCR                      | 67     |
| Creatine Kinase (CK)                                   | 23     | Edoxaban (Lixiana monitoring)                 | 44     |
| Creatinine   | 23, 95 | EGFR Mutation (exons 18-21 hotspots)          | 76     |
| Creatinine Clearance                                   | 23, 95 | Electron Microscopy (EM)                      | 62     |
| Crossmatch   | 18     | EMA binding test                              | 60     |
| Cryptococcal Antigen                                   | 52     | Entamoeba histolytica Ab-lgG                  | 53     |
| CSF routine analysis (WBC, D/C, RBC, Glucose, Protein) | 58     | Enteric Pathogens Detection by Multiplex PCR  | 69     |
| CSF- Albumin   | 22     | Eosinophil                                    | 41     |
|  |        |   |        |

| Eosinophilia Panel                                | 73 |
|---|----|
| Estimated glomerular filtration rate (eGFR)       | 25 |
| Estradiol   | 95 |
| Estradiol (E2)                                    | 25 |
| Factor II   | 43 |
| Factor II (G20210A) Mutation                      | 75 |
| Factor II & V Leiden Mutations                    | 75 |
| Factor IX   | 43 |
| Factor V  | 43 |
| Factor V Leiden (G1691A) Mutation                 | 75 |
| Factor VII  | 43 |
| Factor VIII                                       | 43 |
| Factor X  | 43 |
| Factor XI   | 43 |
| Factor XII  | 43 |
| Factor XIII                                       | 43 |
| FAP APC & MUTYH Full Gene Mutation by NGS (Blood/ | 78 |
| FFPE)   |    |
| Ferritin  | 25 |
| Fetal red cells in maternal circulation           | 61 |
| FFPE Blood Panel (4 probes)                       | 75 |
| FFPE FISH Panel (4 probes)                        | 80 |
| Fibrinogen (Clauss Assay)                         | 43 |
| Fibrinogen antigen                                | 25 |
| Fibrinogen degradation products (FDP)             | 43 |
| Fine Needle aspiration (FNA)                      | 65 |
| FLT3-ITD & TKD Mutation                           | 70 |
| Folate  | 95 |
| Folate, RBC                                       | 25 |
| Free Protein S Ag                                 | 44 |
|   |    |

| Free T3   | 95 |
|---|----|
| Free T4   | 95 |
| Frozen section  | 66 |
| FSH   | 95 |
| Fungus Culture  | 46 |
| Fungus Smear  | 46 |
| Fusion Panel by NGS   | 70 |
| Gentamicin  | 95 |
| Glucose   | 95 |
| GPIIb/IIIa and GP1b/V/IX detection  | 61 |
| Gram Stain  | 46 |
| Group   | 17 |
| Group B Beta-streptococcus Screen (GeneXpert) & GBS C&ST                    | 46 |
| H. pylori Ab-IgG  | 53 |
| H. pylori Antigen   | 53 |
| H. pylori Culture & Sensitivity   | 47 |
| Haemoglobin   | 41 |
| Haemoglobin pattern (quantification of HbA2, HbF, detection of Hb variants) | 42 |
| HBV ADV and ETV Drug Resistance   | 67 |
| HBV DNA Quantitative PCR  | 67 |
| HBV YMDD Mutation   | 67 |
| HCT   | 41 |
| HCV RNA Genotyping  | 67 |
| HCV RNA Quantitative RT-PCR   | 67 |
| HDL-cholesterol   | 95 |
| Hematopoietic Progenitor Cells (Apheresis) Processing                       | 59 |
| and Cryopreservation  |    |
| Hematopoietic Progenitor Cells (Apheresis) Thawing                          | 59 |

| Hemoclot Thrombin Inhibitor (Dabigatran monitoring)    | 44     |
|--|--------|
| Heparin monitoring (Anti-Xa Assay)                     | 44     |
| Hepatitis B virus surface antigen (HBsAg) quantitative | 28     |
| Hepatitis C virus antibody (HCV)                       | 28     |
| HER2 Mutation (exon 20)                                | 76     |
| High density lipoprotein cholesterol (HDL-C)           | 28     |
| High sensitive C-Reactive protein (hs-CRP)             | 28     |
| High-Risk HPV DNA PCR                                  | 67     |
| HIV RNA Quantitative RT-PCR                            | 67     |
| Homocysteine   | 28, 95 |
| HPV DNA Genotyping                                     | 67     |
| HSV 1 Specific Ab-IgG                                  | 53     |
| HSV 2 Specific Ab-IgG                                  | 54     |
| Human Epididymis protein (HE4)                         | 28     |
| Human growth hormone                                   | 28, 29 |
| Human immunodeficiency virus antibody/p24 antigen      | 29     |
| (HIV Ag/Ab)  |        |
| Human Papilloma Virus (HPV)                            | 64     |
| IDH1 & IDH2 Hotspots Mutation                          | 79     |
| IDH1 and IDH2 hotspots Mutation                        | 71     |
| IDH1 R132 Mutation                                     | 71     |
| IDH2 R140 & R172 Mutation                              | 71     |
| IG and TCR detection(B+T cell clonality)- Blood        | 73     |
| IG and TCR detection(B+T cell clonality)- FFPE         | 73     |
| IgG & IgM  | 49     |
| IGH / IGK detection (B-cell clonality) *(blood)        | 73     |
| IGH::CCDN1 t(11;14) FISH                               | 73     |
| IGHV Somatic Hypermutation *(blood)                    | 72     |
| Immunofixation   | 29     |
| Immunofluorescence (IF)                                | 62     |
|  |        |

| 29     |
|--------|
| 29     |
| 29     |
| 29     |
| 29     |
| 29     |
| 62     |
| 47     |
| 17     |
| 29, 95 |
| 29, 95 |
| 30, 95 |
| 74     |
| 74     |
| 58     |
| 70     |
| 79     |
| 71     |
| 79     |
| 76     |
| 30     |
| 30     |
| 95     |
| 54     |
| 60     |
| 95     |
| 30     |
| 30     |
| 76     |
| 76     |
|        |

| Lung Cancer-Combo (LCMAP-Combo)  | 76     |
|--|--------|
| Lupus anticoagulant  | 44     |
| Lutinizing hormone (LH)  | 30, 31 |
| Lymphocyte   | 41     |
| Lymphocyte subsets study including CD4 cell count                      | 60     |
| lymphoma Immunophenotyping   | 60     |
| Macrolide-Resistant Mycoplasma pneumoniae PCR                          | 68     |
| Magnesium  | 31,95  |
| Malaria p.f./p.v. Antigen by immunoassay                               | 42     |
| Malaria Parasites  | 42     |
| MCH  | 41     |
| MCHC   | 41     |
| MCV  | 41     |
| MDS FISH Panel   | 74     |
| Measles Ab-IgG   | 54     |
| Measles virus PCR  | 68     |
| Meningitis/Encephalitis Pathogen Detection by                          | 69     |
| Multiplex PCR  |        |
| MET exon 14 skipping   | 76     |
| Methaemoglobin   | 31     |
| Methotrexate   | 31     |
| MGMT Promoter Methylation by MLPA                                      | 79     |
| Microalbumin   | 31,32  |
| Microalbumin to creatinine ratio                                       | 32, 96 |
| Microsatellite Instability (MSI)                                       | 78     |
| Microscopic Examination of Crystals                                    | 47     |
| Microscopy for Demodex   | 47     |
| Minimal residual disease testing                                       | 60     |
| MLH1 / MSH2 / PMS2 / MSH6 / APC / MUTYH Known<br>Mutation (Blood/FFPE) | 78     |

| MLH1 / MSH2 / PMS2 / MSH6 Promoter Methylation by MLPA (Blood/FFPE) | 79     |
|---|--------|
| MLH1/ MSH2/ PMS2/ MSH6/ APC/ MUTYH large                            | 79     |
| genomic rearrangement detection by MLPA (Blood)                     |        |
| MM FISH Panel   | 73     |
| MMR genes by NGS (Blood/ FFPE)                                      | 78     |
| MONO Blood FISH (1 probe)   | 75     |
| MONO FFPE FISH (1 probe)  | 80     |
| Monocyte  | 41     |
| Monospot Test (Heterophile Ab-IgM)                                  | 54     |
| Mosquito-borne Pathogen Detection by Multiplex PCR                  | 69     |
| MPD Panel - BCR::ABL1 p190 & p210 RT-PCR, JAK2 exon                 | 74     |
| 14 V617F, CALR exon 9   |        |
| MPL exon 10 \$505 and W515 Mutation                                 | 74     |
| MRD Single Variant (by ddPCR)                                       | 71     |
| MRD Single Variant (by NGS)   | 70     |
| MRSA Screen   | 47     |
| MRSA Screen (GeneXpert) & MRSA C&ST                                 | 47     |
| MTB-Nucleic Acid Detection  | 47     |
| MTB/RIF resistance (GeneXpert)                                      | 47     |
| Muscle Biopsy   | 62     |
| Mycoplasma hominis & Ureaplasma urealyticum C&ST                    | 47     |
| Mycoplasma pneumoniae Ab-IgM  | 54     |
| MYD88 exon 5 L265P Mutation   | 74     |
| Myeloid Panel + Rapid Aneuploidy Screen                             | 70     |
| Myeloid Panel by NGS  | 70     |
| Myoglobin   | 32     |
| N-terminal prohormone of brain natriuretic peptide                  | 32, 33 |
| (NT-proBNP)   |        |
| Neisseria gonorrhoeae PCR   | 67     |

| Neonatal Bilirubin                                  | 32 | Phenytoin (Dilantin)                                | 96     |
|---|----|---|--------|
| Netilmicin  | 96 | PIK3CA Mutation (exons 9 & 20)                      | 76     |
| Neutrophil  | 41 | Platelet  | 41     |
| NGS-BREAST PANEL - 9 genes (Blood)                  | 77 | Pleural fluid routine analysis (pH, WBC, D/C, RBC,  | 58     |
| Non-HDL-Cholesterol                                 | 32 | Glucose, Protein)                                   |        |
| NPM1 exon 12 Mutation                               | 70 | Pleural fluid-Adenosine deaminase                   | 33     |
| NRAS Mutation                                       | 78 | Pleural fluid-Glucose                               | 33     |
| NT-proBNP   | 96 | Pleural fluid-Lactate dehydrogenase (LDH)           | 33     |
| Occult Blood  | 48 | Pleural fluid- Protein                              | 33     |
| Osmolality  | 96 | PML::RARA L and S-isoform RT-PCR                    | 72     |
| Osmolality, plasma                                  | 33 | PML::RARA L-isoform bcr1 / bcr2 quantitative RT-PCR | 72     |
| Osmolality, urine                                   | 33 | PML::RARA S-isoform bcr3 quantitative RT-PCR        | 72     |
| Osteocalcin   | 33 | Pneumocystis jirovecii PCR                          | 68     |
| Other body fluid analysis (pH, WBC, D/C, RBC)       | 58 | Pneumonia Panel by Multiplex PCR                    | 68     |
| Other molecular test by special request             | 80 | PNH analysis  | 60     |
| Oximetry  | 61 | Polysomnography                                     | 61     |
| Pap smear (BD SurePath Liquid-based Pap Test)       | 64 | Potassium   | 33     |
| Pap smear (Conventional method)                     | 64 | Prealbumin  | 33     |
| Parasite Antigen Screen (Giardia. Entamoeba         | 54 | Pregnancy test                                      | 48     |
| histolytica, Crytosporidium)                        |    | Private Donor                                       | 18     |
| Parathyroid hormone (PTH)                           | 33 | Procalcitonin                                       | 34     |
| Parvovirus B19 Ab-IgG                               | 54 | Progesterone  | 34, 96 |
| Parvovirus B19 Ab-IgM                               | 55 | Prolactin   | 34     |
| Pathogen identification by direct sequencing        | 69 | Prolactin   | 96     |
| PCM1::JAK2 RT-PCR                                   | 75 | Prostate specific antigen, free (F-PSA)             | 34     |
| PDGFRA Mutation                                     | 79 | Prostate specific antigen, total (PSA)              | 34     |
| Peritoneal washing                                  | 66 | Protein   | 96     |
| Ph-MPD Panel - JAK2 exon 14 V617F, CALR exon 9, MPL | 74 | Protein C Activity                                  | 44     |
| exon 10 S505 and W515 (reflex testing)              |    | Protein electrophoresis                             | 34     |
| Phenobarbital                                       | 96 | Protein, total                                      | 35     |
| Phenytoin   | 33 | Prothrombin time (PT) & INR                         | 42     |
|   |    | • •   |        |

| PTH  | 96 |
|--|----|
| QuantiFeron-TB Gold  | 55 |
| Quantitative Test  | 96 |
| Rapid Aneuploidy Screen  | 70 |
| Rapid Influenza A & B and RSV Screen                           | 55 |
| RBC  | 41 |
| RBC-G6PD   | 96 |
| RDW  | 41 |
| Real-time PCR detection for Influenza A, H1N1pdm09, H3N2       | 68 |
| Real-time PCR detection for Influenza A, H1N1pdm09, H3N2, H5N1 | 68 |
| Real-time PCR detection for Influenza B Virus                  | 68 |
| Real-time Reverse Transcription PCR for SARS-CoV-2             | 68 |
| Renal Biopsy   | 63 |
| Respiratory Pathogen Panel by Multiplex PCR                    | 68 |
| Ret Hb Content   | 42 |
| Reticulocyte Count   | 42 |
| Rh (D) typing  | 17 |
| Rheumatoid factor (RF)   | 35 |
| Rivaroxaban (Xarelto monitoring)                               | 44 |
| Rubella virus IgG  | 35 |
| Rubella virus IgM  | 35 |
| RUNX1::RUNX1T1 quantitative RT-PCR - t(8;21)                   | 70 |
| RUNX1::RUNX1T1 RT-PCR - t(8;21)                                | 70 |
| Salicylate (Aspirin)   | 96 |
| SARS-CoV-2 Neutralizing  | 55 |
| SARS-CoV-2 virus IgG   | 35 |
| SARS-CoV-2 virus IgG quantitative                              | 35 |
| SARS-CoV-2 virus IgM   | 35 |

| Seminal Fluid Routine Analysis                               | 55 |
|--|----|
| Serum free light chains                                      | 35 |
| Serum IgA heavy light chain pair assay                       | 35 |
| Serum IgG heavy light chain pair assay                       | 36 |
| Serum IgM heavy light chain pair assay                       | 36 |
| Serum immunofixation   | 36 |
| Sirolimus  | 36 |
| Skin Biopsy  | 63 |
| SleepView  | 61 |
| Sodium   | 36 |
| Soluble Transferrin Receptor (sTfR)                          | 36 |
| Somatic BRCAI & BRCA2 Mutation by NGS                        | 77 |
| Special staining   | 63 |
| Sputum   | 66 |
| STAT3 & STAT5b Mutation                                      | 75 |
| Stool routine  | 48 |
| Streptococcus pneumoniae Antigen                             | 56 |
| Streptococcus pyogenes Group A Antigen                       | 56 |
| Strongyloides Ab-IgG   | 56 |
| Syhpilis RPR   | 56 |
| Syphilis Treponema pallidum total antibody (TPAb)            | 36 |
| Syphilis VDRL  | 56 |
| Systemic Sclerosis Profile (Anti-Scl-70, Anti-CENP A, Anti-  | 56 |
| CENP B, Anti-RP11, Anti-RP155, Anti-Fibrillarin, Anti-NOR90, |    |
| Anti-Th/To, Anti-PM-Scl-100, Anti-PM-Scl-75, Anti-Ku, Anti-  |    |
| PDGFR, Anti-Ro-52)   |    |
| T.P.P.A. for Syphilis  | 57 |
| T3   | 96 |
| T4   | 96 |
| Tacrolimus   | 36 |
| Targeted genes by NGS (Blood/FFPE)                           | 77 |

| TcCO2   | 61     |
|---|--------|
| TCR gene rearrangement (T-cell clonality) *(blood)    | 73     |
| Testosterone  | 37, 96 |
| Theophylline  | 96     |
| Thrombin Time (TT)                                    | 42     |
| Thyroglobulin   | 37     |
| Thyroid stimulating hormone (TSH)                     | 37     |
| TIBC  | 96     |
| Tobramycin (Nebcin)                                   | 96     |
| Total iron binding capacity (TIBC)                    | 38     |
| Total procollagen-type 1 N-terminal-propeptide (P1NP) | 38     |
| Total T3  | 38     |
| Total T4  | 38     |
| TP53 Mutation (Full gene)                             | 72     |
| TPO Antibodies  | 57     |
| Transferrin   | 38     |
| Trephine Reporting by Hosp. Haematologist             | 45     |
| Trichomonas & Monilia                                 | 48     |
| Triglycerides   | 38     |
| Triglycerides   | 96     |
| TRIO Blood FISH (3 probes)                            | 75     |
| TRIO FFPE FISH (3 probes)                             | 80     |
| Troponin I  | 38     |
| Troponin T  | 38     |
| Tryptase  | 38     |
| TSH   | 96     |
| TSH Receptor Ab-IgG                                   | 57     |
| Type & Screen   | 18     |
| Urea  | 39, 96 |
| Urea Breath Test                                      | 18     |

| ric acid   | 39, 96 |
|--|--------|
| rine   | 66     |
| rine albumin-to-creatinine ratio                   | 39     |
| rine Bence Jones protein                           | 39     |
| rine immunofixation                                | 39     |
| rine protein-to-creatinine ratio                   | 39     |
| rine routine                                       | 48     |
| alproic acid                                       | 39     |
| alproic Acid (Epilim)                              | 96     |
| ancomycin  | 39, 96 |
| aricella Zoster Virus IgG                          | 57     |
| erifyNow Aspirin response                          | 45     |
| erifyNow Plavix response                           | 45     |
| iral Enteric Pathogens PCR (Norovirus & Rotavirus) | 69     |
| itamin B12   | 39, 96 |
| itamin D (25-OH) total                             | 40     |
| on Willebrand factor Activity                      | 44     |
| on Willebrand factor antigen                       | 44     |
| RE Screen  | 48     |
| /arm Agglutinin                                    | 17     |
| /ATCH-PAT 100                                      | 61     |
| /BC Count  | 41     |
| /eil-Felix Test                                    | 57     |
| /idal Test   | 57     |
| hCG  | 96     |
|  |        |



#### **Department of Pathology**

Address: Hong Kong Sanatorium & Hospital

1/F, Li Shu Fan Block

2 Village Road, Happy Valley, Hong Kong

Tel: 2835 8790 Fax: 2835 8799 Email: lab@hksh.com

https://www.hksh-hospital.com/

